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Abstract
The liver is the commonest site of metastatic disease for patients with colorectal 
cancer, with at least 25% developing colorectal liver metastases (CRLM) during 
the course of their illness. The management of CRLM has evolved into a complex 
field requiring input from experienced members of a multi-disciplinary team 
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involving radiology (cross sectional, nuclear medicine and interventional), 
Oncology, Liver surgery, Colorectal surgery, and Histopathology. Patient 
management is based on assessment of sophisticated clinical, radiological and 
biomarker information. Despite incomplete evidence in this very heterogeneous 
patient group, maximising resection of CRLM using all available techniques 
remains a key objective and provides the best chance of long-term survival and 
cure. To this end, liver resection is maximised by the use of downsizing 
chemotherapy, optimisation of liver remnant by portal vein embolization, 
associating liver partition and portal vein ligation for staged hepatectomy, and 
combining resection with ablation, in the context of improvements in the 
functional assessment of the future remnant liver. Liver resection may safely be 
carried out laparoscopically or open, and synchronously with, or before, 
colorectal surgery in selected patients. For unresectable patients, treatment 
options including systemic chemotherapy, targeted biological agents, intra-
arterial infusion or bead delivered chemotherapy, tumour ablation, stereotactic 
radiotherapy, and selective internal radiotherapy contribute to improve survival 
and may convert initially unresectable patients to operability. Currently evolving 
areas include biomarker characterisation of tumours, the development of novel 
systemic agents targeting specific oncogenic pathways, and the potential re-
emergence of radical surgical options such as liver transplantation.
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Core Tip: The management of colorectal liver metastases is a complex evolving field 
requiring input from an experienced multi-disciplinary team involving radiology (cross 
sectional, nuclear medicine and interventional), Oncology, Liver surgery, Colorectal 
surgery, and Histopathology. Patient management is based on clinical, radiological and 
biomarker information. Despite incomplete evidence in this very heterogeneous patient 
group, maximising resection of colorectal liver metastases using all available techniques 
remains a key objective and provides the best chance of long-term survival. For 
unresectable patients, optimal systemic and locoregional chemotherapeutic, biological and 
radiotherapeutic treatments improve survival, and may convert initially unresectable 
patients to operability.
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Colorectal cancer (CRC) represents a major worldwide health care burden, as the 
second most common cancer diagnosed in women and third most common in men, 
and accounting for 10% of all annually diagnosed cancers and cancer-related deaths 
worldwide[1].
As result of improvements in detection through screening[2], better referral 
pathways[3], centralisation of services[4], effective primary surgery[5], development of 
systemic chemotherapy[6], biological agents[7], and understanding of tumour biology[8], 
survival rates following diagnosis have improved[9].
Nevertheless, at least 25%-50% of patients with CRC develop colorectal liver 
metastases (CRLM) during the course of their illness.
From a historical perspective, the surgical management approach to CRLM has 
undergone a significant evolution. Starting from an era prior to the 1930s during 
which liver surgery for malignancy presented insurmountable challenges for technical 
and oncological reasons, tentative attempts at liver resection for malignancy were 
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made in the subsequent decades resulting in early reports establishing proof of 
principle that long term survival following resection of CRLM was possible[10,11]. These 
results were confirmed and emphasised by larger landmark studies firmly establishing 
liver surgery as a potentially curative treatment for CRLM[12,13].
The era since has been characterised by progress in understanding of tumour 
biology as well as surgical and oncological developments. These overlapping and 
interdependent factors have directed the modern management of CRLM to a 
multidisciplinary approach involving radiology (cross sectional, nuclear medicine and 
interventional), Oncology, Liver surgery, Colorectal surgery, Histopathology, and 
Specialist  nursing[14]. The paramount importance of the MDT cannot be 
overemphasised as it represents the forum where key management decisions are made 
after consideration of information spanning many different disciplines, with 
demonstrable benefits in terms of significant treatment alterations[15,16], numbers of 
patient offered resection[17,18], and ultimately translating into improved survival[19,20].
In the following review, we present modern management of CRLM. In order to 
assist the reader, section contents are provided below: (1) Diagnosis and staging of 
CRLM post resection of CRC; (2) Tumour characterisation and biomarkers in CRC; (3) 
Systemic and locoregional chemotherapy and targeted agents in CRLM management; 
(4) Surgical management of resectable CRLM; and (5) Histopathological assessment of 
resected CRLM.
SECTION 1: DIAGNOSIS, STAGING, AND SURVEILLANCE OF 
COLORECTAL LIVER METASTASES POST RESECTION
The detection of CRLM is achieved during staging investigations in the case of 
synchronous CRLM and by post CRC resection surveillance programmes in the case of 
metachronous CRLM. The section below discusses the timing and epidemiology of 
metachronous CRLM, an understanding of which is essential in judging the 
effectiveness of post CRC resection surveillance practice. The section also describes 
current optimal staging of CRLM, and finally current practice as it applies to 
surveillance after resection of CRLM.
CRLM epidemiology
Colorectal cancer is the third most common cancer worldwide and accounts for 10% of 
all cancers. It is a major cause of morbidity and the second most common cause of 
cancer related mortality[1].
Although it is regularly reported that approximately 50% of patients with colorectal 
cancer develop liver metastases, either as synchronous or metachronous disease[21-25], 
this is likely an exaggeration of true incidence originating from an historic autopsy 
study of patients who died with colorectal cancer[26]. Large epidemiological studies 
from multiple European centres demonstrate the incidence of both synchronous and 
metachronous liver metastases in patients with colorectal cancer to be lower, at 
approximately 25%[27-31]. The incidence of synchronous liver metastases in 
epidemiological studies ranges from 13.8%–17.1%[27,29,30] and the rate of metachronous 
liver metastases in these studies ranges from 7.6%–15.1%[27,29,30,32]. The interval between 
primary diagnosis and the detection of metastatic disease used in the literature ranges 
from the time of primary resection[29], to 3 mo[29,33], or 6 mo after diagnosis, and this lack 
of a consensus regarding the definition of metachronous metastases may partly 
explain the reported variation[24,32]. Further confounders include evolution in the 
sensitivity of pre-operative staging, and the reported increase in synchronous 
disease[28]. CRLM occur more frequently in male patients and in patients with left sided 
CRC, relating to embryological origin of the primary tumour[27,30].
With regards to metachronous disease, most recurrences occur early in follow up: 
76%-85.3% occur within a year and 83%-97.5% within 3 years, with 30%-40% of 
patients having disease confined to the liver[33,34]. Approximately 2% of patients will 
develop liver metastases between 5 and 10 years after resection of the primary 
tumour[27,29,33].
CRC surveillance programmes
Surveillance programmes accompanied the widespread introduction of liver resection 
for CRLM, to detect recurrent disease early, with a view to improve survival. A meta-
analysis of five randomised controlled trials published in 2002 supported this 
hypothesis by demonstrating a survival benefit associated with more intensive follow 
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up regimes[35]. This encouraged the introduction of more intensive surveillance 
programmes, although a subsequent large multicentre randomised control trial 
performed in the United Kingdom by Primrose et al[36] failed to replicate these findings. 
In this study, intensive surveillance regimes with computed tomography (CT) with or 
without carcino-embryonic antigen (CEA) resulted in an increased rate of surgical 
treatment with curative intent, but this failed to translate to improved survival when 
compared to the minimal surveillance group[36]. Interestingly, the reported incidence of 
metachronous disease in this study was markedly lower than that reported in the 
previous meta-analysis (8.4% vs 32%). The stage-specific case mix and risk of 
recurrence within tumour stage across studies remained similar but one explanation 
for this reported difference was possibly superior pre-operative staging. This would 
provide an explanation for the previously reported improved benefit of more intensive 
follow up programmes with early recurrence in these older studies representing 
undetected residual disease[36]. A further meta-analysis published in 2016 of 15 
randomised controlled trials came to a similar conclusion to that of Primrose et al[36] 
and demonstrated no overall survival benefit with more intensive follow up 
regimes[36,37].
In summary, surveillance programmes with either regular CEA or CT increase the 
likelihood of detecting recurrent disease and result in an increased proportion of 
patients undergoing surgical treatment with curative intent. This has not, however, 
been shown to translate into improved patient survival in trials. This counter-intuitive 
finding may partially be explained by the failure of randomised trials to detect small 
differences: If 25% of patients develop CRLM post CRC resection, of which 25% are 
operable, and of which 25% are 10 year survivors, the difference in overall survival in 
a surveillance group may prove beyond detection. In practice, the real world 
observation of lives saved following resection of metachronous CRLM has resulted in 
the continued adoption of surveillance programmes using CT and serum CEA, 
although the additional value of the latter has been difficult to demonstrate in trials[36].
CRLM characterisation and staging
Imaging has an important role in defining optimal treatment of CRLM. Knowing the 
size, location and vascular relationships of CLRM is essential prior to treatment 
planning and assessment of neoadjuvant response. Imaging techniques include 
ultrasound, CT, magnetic resonance imaging (MRI) and fluoro-18-deoxyglucose (FDG) 
positron emission tomography (PET-CT).
Ultrasound: Ultrasound has a limited role in pre-operative evaluation as it has a low 
sensitivity (64%) for CRLM compared with other imaging modalities[38]. In recent years 
contrast-enhanced ultrasound (CEUS) has become widely used to characterise liver 
lesions based on dynamic assessment of tumour vascularity. CEUS has a reported 
sensitivity of 80%–90%, comparable to CT and is significantly more sensitive than 
grey-scale ultrasound for detecting small CRLM less than 10 mm[39,40]. Nevertheless, 
CEUS does not offer comprehensive information needed for surgical planning as 
compared to CT or MRI. Intra-operative ultrasound (IOUS) has an established role in 
lesion detection and mapping of major hepatic vessels during surgery. IOUS has been 
shown to identify new lesions in 16% of patients and alter clinical management in 
9%[41]. Contrast enhanced IOUS has higher sensitivity and specificity than traditional 
IOUS particularly for detection of “disappearing” lesions in the setting of neoadjuvant 
therapy[42,43].
Computed tomography: CT is the modality of choice for detection of liver and 
extrahepatic metastases. The high spatial resolution of CT combined with isotropic 
pixel size enables reformatted images in various planes, which enables better 
delineation of tumour and adjacent vascular structures for accurate segmental 
localisation[44]. The portal venous phase (approximately 60-70 s after administration of 
contrast agent) is the most reliable phase for detection of CRLM with a detection rate 
of 85% and a positive predictive value of 96%[45]. CRLM are typically hypovascular 
with variable heterogeneity depending on size and previous treatment. Since CRLM 
are hypovascular, arterial phase imaging does not improve detection but is helpful for 
pre-surgical or pre-embolisation planning[46]. The performance of CT is somewhat 
limited in detecting CRLM < 10 mm which are interpreted as too small to 
characterise[47]. In addition fatty liver is not uncommon post chemotherapy which can 
further limit detection of liver metastases.
Magnetic resonance imaging: Compared to CT, MRI has superior soft tissue contrast 
which makes it an invaluable tool for detection and characterisation of CRLM 
particularly those below < 10 mm[48]. CRLM are typically T1-hypointense, mildly T2-
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hyperintense with heterogeneous but predominantly rim enhancement in the arterial 
phase and hypo-enhancement in portal venous and delayed phases. Two advances 
which have revolutionised the role of MRI in the last decade are diffusion weighted 
imaging (DWI) and the use of hepatocyte-specific contrast agents. DWI measures the 
mobility of water molecules in tissues. Apparent diffusion coefficient values are 
quantitative estimates of diffusion restriction. CRLM show restricted diffusion of 
water molecules due to their hypercellular nature which manifests as high signal 
intensity lesions with low apparent diffusion coefficient values. Addition of DWI 
improves sensitivity and specificity for lesion detection and characterisation[49,50]. 
Hepatocyte-specific contrast agents are highly sensitive for detection of small lesions, 
which may be virtually occult on other sequences[51]. This also allows for detection of 
“disappearing” lesions which can mimic complete response to neoadjuvant therapy[52]. 
Gadobenate dimeglumine (MultiHance, Bracco) and gadoxetate disodium (Eovist, 
Bayer) are both hepatocyte-specific contrast agents which are preferentially taken up 
by hepatocytes and excreted into the biliary tree. In the delayed hepatobiliary phase 
(10–120 min after administration) normal hepatocytes are hyperintense compared to 
liver metastases, which do not retain the contrast agent. DWI has similar sensitivity 
and specificity as MRI with extracellular contrast agent but lower sensitivity than MRI 
with hepatocyte-specific contrast agent[53].
Positron emission tomography/computed tomography: There is lack of clinical 
evidence to show that Fluorine18 labelled Positron Emission Tomography/Computed 
Tomography (18FDG PET-CT) has significant impact on the clinical management of 
localised non-metastatic colorectal cancer preoperatively[54]. Its role in the initial 
assessment colorectal cancer, therefore, is not yet established[55]. Most centres do not 
carry out a routine 18FDG PET-CT at this stage.
18FDG PET-CT is considered to be very accurate and sensitive in the detection of 
CRLM, especially those greater than 10 mm[56]. However, small liver metastases (< 10 
mm) and liver metastases from some mucinous adenocarcinomas can be missed[57-59].
18FDG PET-CT has been found to be accurate in identifying extrahepatic metastasis. 
Some studies suggest addition of 18FDG PET-CT can lead to change in management in 
over one-third of patients avoiding unnecessary metastasectomy[60-62], with a significant 
impact on survival[63]. However, other studies have disputed this and found only a 
modest 8% change in surgical management with 6% of false positive findings[64,65]. The 
role of 18FDG PET-CT in addition to standard imaging of CT chest, abdomen and 
pelvis, and MR liver in presurgical patients remains uncertain. Some authors have 
proposed it could be used as problem solving modality[66] to identify extrahepatic 
metastases in high risk patients[48]. Despite its shortcomings, 18FDG PET-CT remains 
part of our imaging algorithm prior to hepatic metastasectomy.
There is insufficient evidence for the use 18FDG PET-CT on routine surveillance, 
however, it does have a supplementary role in the context of rising CEA if CT fails to 
identify the site of disease[67].
Surveillance after resection of CRLM
Given that over half of patients undergoing liver resection for CRLM develop 
recurrence[68], that approximately half of these are hepatic only[69], and in the light of 
favourable outcomes after re-hepatectomy (see section 4) for intra hepatic recurrence, 
there is an intuitive and logical justification for surveillance following resection of 
CRLM. However, there is considerable heterogeneity in surveillance practice[70], and 
concerns have been raised regarding the implications of irradiation[71] and health care 
costs[72].
Defining optimal surveillance requires a knowledge of when recurrence occurs, and 
how best to detect it. In a retrospective multi-institution cohort study of 2320 patients 
undergoing initial hepatectomy for CRLMs, Hallet et al[73] reported that 89.1% of 
recurrences developed within 3 years. Recurrence was intrahepatic in 46.2%, 
extrahepatic in 31.8% and combined intra/extrahepatic in 22%.
Despite this concentration of recurrence in the early years, and many surveillance 
protocols suggesting follow up for 5 years[69,74], there is consistent evidence of 
recurrence occurring beyond 5 years in a significant minority of patients. Pulitanò 
et al[75] reported that whilst 93% of recurrences occurred within the first 5 years of 
follow-up, 11% of patients who were disease-free at 5 years developed later 
recurrence. Similarly, Tomlinson et al[76] found that of patients who were found to be 
disease free at 5 years, 23% had a documented first recurrence after 5 years, and 
Viganò et al[77] reported that 15% of the patients disease-free at 5 years developed later 
recurrence.
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Heterogeneity applies not only to length of surveillance but also to surveillance 
type, reflecting the lack of evidence in this area.
However, in a prospective study of 76 patients, Bhattacharjya et al[78] reported that 
the use of CT or tumour markers CEA alone failed to demonstrate early recurrence in 
12 and 18 patients respectively, and that the combination of tumour markers and CT 
detected significantly more recurrence than either modality alone, thus supporting the 
combination of CT and CEA in the follow-up of patients with resected colorectal liver 
metastases.
In an attempt to rationalise surveillance in long term survivors, Galjart et al[74] 
produced a stratification risk score based on primary nodal status and disease free 
interval between primary and CRLM resection to determine surveillance intensity. The 
authors found that in patients who were disease free after 5 years, recurrence rate 
beyond 5 years was 3% in the low risk group, but 12% in the high-risk group.
The role of other modalities such as MRI or PET-CT in post-operative surveillance is 
not defined but is predominantly used to investigate, confirm and characterise 
recurrence where it is suspected from CT and CEA results.
In conclusion recurrence after resection of CRLM is frequent and occurs mostly in 
the first 3 years post resection. Nevertheless, up to 23% of patients who are diseased 
free at 5 years may develop recurrence thereafter, such that protocols ending 
surveillance at 5 years would miss those patients. Generating good evidence for 
optimal length, frequency, and type of surveillance is likely to be challenging, and 
surveillance protocols are likely to be determined by clinician/patient preference as 
well as health care system resource issues.
SECTION 2: TUMOUR CHARACTERISATION AND BIOMARKERS IN 
COLORECTAL CANCER
The development of liver resection for CRLM has stimulated attempts to identify 
prognostic factors to aid in patient selection. Such factors have included primary CRC 
characteristics (tumour site, TNM stage), CRLM characteristics (size of largest liver 
metastasis, number of lesions, grade of differentiation, margin status), and other 
factors such as CEA, presence of additional extra-hepatic disease, and time interval 
between the emergence of CRC and CRLMs[79-82]. The limitations of individual factors 
in prognostication prompted their combination to produce risk scores such as the Fong 
score[83], however even this was found wanting in terms of prognostication[84-86]. It 
seems likely that the prognostic shortcomings of clinical criteria reflect the fact that 
they are merely surrogate markers for the underlying molecular biological markers 
that truly determine tumour biology.
Although a detailed account of current CRC biomarkers is beyond the scope of this 
review, the following summaries and Figure 1 give an impression of some of the key 
CRC oncogenic pathways (Figure 1A) and the biomarkers KRAS, NRAS, BRAF, TP53, 
PIK3CA, APC, and Mismatch Repair Deficiency (MMRD), chosen for their 
prominence, and also because they inform the rationale for current chemotherapy and 
biological targeting treatments (Figure 1B).
KRAS
KRAS is a GTP-binding protein and the first member of the KRAS-BRAF-MEK-MAPK 
pathway which is activated following binding of ligand to Epidermal Growth Factor 
Receptor (EGFR).
KRAS mutation leads to constitutive activation of the pathway and is one 
mechanism in EGFR blockade resistance. Once acquired, KRAS mutation persists with 
96% concordance between primary tumours and metastases[87].
KRAS mutation (predominantly at codon 12[88] and 13[89]) is present in approximately 
30% of colorectal cancers, and associated with more aggressive disease and more 
frequent recurrence after resection of colorectal liver metastases[90], although the poor 
prognostic effect of mutant KRAS may be limited to left sided primary tumours[81].
In terms of its implications for treatment of colorectal liver metastases, it has been 
reported that mutant KRAS is associated with a higher incidence of positive 
margins[91], with some authors reporting better outcomes in mutant KRAS patients 
whose metastases were resected with wider margins in anatomical (rather than non-
anatomical) resections[92]. However, these results have been challenged with the 
alternative interpretation that the increased recurrence rate in the non-anatomical 
group may have been related to a higher proportion of radiofrequency ablation (RFA) 
treated tumours[91]. Thus it may be that the higher recurrence rate seen in mutant KRAS 
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Figure 1  Biomarkers, molecular pathways, existing and emerging therapeutic targets in colorectal cancer. A: Biomarkers and molecular 
pathways in colorectal cancer. Epidermal Growth Factor Receptor (EGFR) pathway: EGFR is a transmembrane receptor tyrosine kinase[340]. EGF binding to the 
extracellular domain results in activation of down- stream intracellular signalling pathways such as RAS-RAF-MEK-MAPK, and the PI3K PKB mTOR pathway, 
amongst others, which favour cell proliferation and survival[341-344]; Angiogenesis pathway: Vascular endothelial growth factors influence angiogenesis in health and 
disease via binding to the vascular endothelial growth factor receptor. Deregulated angiogenesis impacts on progression in solid tumours, thus providing potential 
anti-angiogenic therapies[345]; Wnt pathway: The Wnt genes are vast family of highly conserved genes with wide ranging roles in development, cell proliferation and 
migration and tumorigenesis[346]. Beta catenin accumulation in the cytoplasm and nucleus leads to cell proliferation. Excess beta catenin accumulation is prevented by 
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its destruction by the “beta catenin destruction complex” (a multiprotein assembly containing adenomatous polyposis coli and GSK3). Wnt binding to its receptor 
frizzled leads to impaired function of the Beta catenin destruction complex and hence beta catenin accumulation and cell proliferation[347]. Mutations in adenomatous 
polyposis coli prevent the formation of the beta catenin complex, and therefore allow beta catenin accumulation and cell proliferation. PI3K inhibits the function of 
GSK3[112], thereby impairing the beta catenin destruction complex, hence contributing to the tumorigenic accumulation of beta catenin. B: Existing and emerging 
therapeutic targets in colorectal cancer pathways. B: Cetuximab and Panitumumab are monoclonal antibodies targeting the EGFR, thus blocking activation of 
downstream signalling pathways. Mutated and constitutively active downstream effectors (such as RAS and RAF) confer resistance to EGFR blockade. Erlotinib and 
gefitinib are EGFR Tyrosine kinase inhibitors and are associated with improved PFS when combined to Bevacizumab in the DREAM trial[156]. Vemurafenib is a RAF 
inhibitor which in combination with EGFR blockade[157] has shown marked responses in some case reports[158]. Selumetinib is a MEK kinase inhibitor showing tumour 
response in some patients with KRAS mutant colorectal cancers progressing on Oxaliplatin[159]. Regorafenib inhibits is a multi-kinase inhibitor[153], with OS benefit in 
randomised double blind control trials[154,155]. Bevacizumab is a Monoclonal antibody against VEGFA with the most prominently established role in the treatment of 
metastatic colorectal cancer. Famitinib is a multiple tyrosine kinase inhibitor and targets the vascular endothelial growth factor receptor tyrosine kinase. Monoclonal 
antibodies targeting the VEGF receptors are also under investigation[160]. EGF: Epidermal Growth Factor; EGFR: Epidermal Growth Factor Receptor; EGFR TKI: 
Epidermal Growth Factor Receptor tyrosine kinase inhibitor; K-ras: K-Ras protein (product of the proto-oncogene KRAS); BRAF: BRAF protein (product of the proto-
oncogene BRAF; MEK: Mitogen activated protein kinase which activates MAPK (mitogen-activated protein kinase); VEGF: Vascular endothelial growth factor; 
VEGFR: Vascular endothelial growth factor receptor; PI3K: phosphoinositide 3-kinase; PKB: Protein kinase B; mTOR: Mammalian target of Rapamycin; Wnt: Wnt 
protein product of proto-oncogne Wnt; Frizzled Receptor: Receptor for Wnt; APC: Protein product of the tumour suppressor gene APC (Adenomatous polyposis coli); 
GSK3: Glycogen synthase kinase 3.
patients after resection of colorectal liver metastases is not directly caused by the 
higher positive margin rate, but that the two are manifestations of underlying 
aggressive biology[93].
BRAF
BRAF is part of the mitogen-activated protein kinase cascade (MAPK), downstream 
from KRAS.
BRAF mutation, most commonly at the V600E codon[94], is found in 5%-15% of 
colorectal cancer patients[94] and is associated with aggressive disease, resistance to 
EGFR blockade[95], worse overall survival (OS) in patients with non-metastatic primary 
colorectal cancer[96], and patients with metastatic colorectal cancer treated with 
palliative chemotherapy[97].
As a result of aggressive and often multisite disease associated with BRAF mutation, 
the incidence of BRAF mutation in patients undergoing resection of CRLM is low (2%-
4%). Those patients with BRAF mutation who do undergo liver resection have a worse 
overall survival in comparison to patients with wild type BRAF[98]. The most recent 
and largest case control study[99] suggests this effect is not due to more frequent 
recurrence, but to the lethal multisite recurrence pattern in those patients in whom 
disease recurs.
In spite of these findings, in those patients with BRAF mutation who do undergo 
liver resection, long term survival (37% 5 years, and median survival 40 mo) is 
reported, and compares favourably with systemic chemotherapy[98,99], such that liver 
resection in these highly selected patients is still deemed indicated, though with 
appropriate counselling regarding outcome.
TP53 and combination mutations
TP53 is a tumour suppressor gene, the product of which (P53) plays crucial roles in the 
regulation of the cell cycle, induction of apoptosis, and Deoxyribonucleic acid (DNA) 
repair[100].
The incidence of TP53 mutation in patients with CRLM ranges between 40%-60%[101].
Although many studies have associated altered P53 activity with advanced stage[102] 
and poor survival in primary CRC[103], reports are conflicting in relation to the 
prognostic significance of mutant in patients undergoing resection of CRLM with 
Tanaka et al[104] identifying it as a predictor of poor survival, in contradiction of other 
studies[105]. Thus, although mutation undoubtedly has a key role in the early stages of 
CRC oncogenesis, its part in CRLM specifically is less clear.
The discrepancy in reported studies may also be in part explained by interactions 
between P53 and other mutations, as suggested by the poor prognosis associated with 
the combination of P53 and KRAS[106] in patients undergoing liver resection for CRLM.
Phospoinositide3-kinase catalytic subunit alpha
Phospoinositide3-kinase catalytic subunit alpha (PIK3CA) encodes the subunit of 
phosphoinositide-3 kinase, which controls downstream genes involved in cell 
proliferation and survival[107]. PIK3CA mutations result in loss of apoptosis, increased 
tumour invasiveness[108], and resistance to EGFR blockade[109].
Mutant PIK3CA is reported in 20% of patients with CRLM and associated with 
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shorter time to relapse following resection[110], and significantly worse OS in patients 
harbouring the combination of mutation in PIK3CA and the Adenomatous Polyposis 
Coli gene (APC)[111]. As further discussed in Figure 1 and in the APC section below, 
mutant phosphoinositide-3 kinase inhibits the function of glycogen synthase kinase 3[112], 
thereby impairing the beta catenin destruction complex, hence contributing to the 
tumorigenic accumulation of beta catenin.
APC
APC is one component of a protein complex (the beta catenin destruction complex) 
which degrades beta catenin. Thus APC mutations allow the accumulation beta 
catenin in the cytoplasm and nucleus, resulting in activation of genes promoting cell 
proliferation and tumorigenesis[113].
APC mutation is reported in 50% of patients with CRLM, and, whilst not prognostic 
on its own, is associated with significantly worse OS in patients harbouring the 
combination of mutation in PIK3CA and APC[111].
This effect may be mediated by the fact that mutant PIK3CA inhibits the function of 
Glycogen synthase kinase 3[112], another component of the beta catenin destruction 
complex, thereby contributing to the tumorigenic accumulation of beta catenin.
MMRD
The mismatch repair system is a group of enzymes which repair errors which 
accumulate during DNA replication. When the proteins of the mismatch repair system 
do not function correctly, errors or mutations occur in the DNA. As a result, tumours 
which are mismatch repair deficient have high levels of mutation or are 
“hypermutated”. The most common mismatch repair protein which is altered in 
colorectal cancer is MLH1 which may be mutated in the germline (approximately 15% 
of cases), or absent due to promoter hypermethylation (sporadic, 85% of cases). Other 
proteins which are frequently affected include MSH2, MSH6 and PSM2. Mismatch 
repair deficiency in tumours can be assessed using protein immunohistochemistry or 
by examining microsatellites on DNA using Polymerase chain reaction (microsatellite 
instability)–these tests are highly concordant[114].
Sporadic mismatch repair deficient tumours are more common in older patients and 
in the right colon, and in early stage cancers. Hypermutation leads to production of 
high levels of immune stimulating neoantigens and increased immune infiltrates, 
which in early stage cancers confers a good prognosis. However, in later stages the 
positive prognostic effect of mismatch repair deficiency becomes lost by a process of 
immune editing. Mismatch repair deficient tumours are considered chemo refractory 
and sporadic mismatch repair deficient cancers are often associated with BRAF 
mutations which confer a further negative prognosis. However, the advent of immune 
checkpoint blockade with anti-PD-1 and anti-CTLA4 inhibitory antibodies has 
heralded a new era for the small number of patients with advanced MMRD colon 
cancers[115,116]. Treatment with novel immunotherapy drugs may lead to long term 
remission for these patients.
Interestingly, MMRD colon cancer may less commonly metastasise to the liver than 
non MMRD colon cancer. Many MMR tumours downregulated HLA expression as a 
mechanism of immune evasion, and HLA negative tumours are less common in liver 
metastases. This is believed to be due to the presence of natural killer cells in the liver 
which eliminate cells with an absent “self” phenotype[117].
SECTION 3: SYSTEMIC AND LOCOREGIONAL CHEMOTHERAPY AND 
TARGETED AGENTS IN COLORECTAL LIVER METASTASES 
MANAGEMENT
Introduction
The role of chemotherapy in the overall management of colorectal liver metastases is 
evolving and complex, consistent with the multitude of different but sometimes 
overlapping contexts in which chemotherapy may be considered.
Although evidence exists to guide management in some scenarios, even then 
decision making remains nuanced in the face of heterogeneity within randomised trial 
groups, as well as patient specific factors such as individual chemotherapy tolerance, 
and risks associated with comorbidities.
Seen from the perspective of maximising the chance of liver resection, as the 
treatment which offers the best chance of long-term survival, these different contexts 
Martin J et al. Colorectal liver metastase
WJCO https://www.wjgnet.com 770 October 24, 2020 Volume 11 Issue 10
may be classified into three broad categories, although it is acknowledged that these 
may overlap: (1) Patients with unequivocally unresectable disease; (2) Those with up-
front resectable disease; and (3) Those patients between these 2 ends of the spectrum, 
whose disease is deemed initially unresectable, but with the potential of conversion to 
resectability by downsizing chemotherapy.
The section below discusses chemotherapeutic options for the three categories 
above in the scenario of metachronous colorectal liver metastases, with synchronous 
metastases discussed in a later separate section (see section 4).
Prior to describing options for these broad patient groups, we discuss chemotherapy 
related hepato-toxicity, as this has a significant influence on decision making.
Chemotherapy related toxicity
Chemotherapy associated hepato-toxicity presents in three main entities: Steatosis, 
steato-hepatitis, and sinusoidal obstruction syndrome.
Steatosis: Liver changes associated with fat accumulation in hepatocytes are termed 
“non-alcoholic fatty liver disease”. Whilst indolent in most patients, a progressive 
form of “non-alcoholic fatty liver disease” can lead to steato-hepatitis, and thereafter 
progress to fibrosis and ultimately cirrhosis[118]. 30%-40% of patients treated with 5-
Fluorouracil develop reversible steatosis demonstrated radiologically and 
histologically[119-121]. Steatosis is associated with increased complications post liver 
resection, though not increased mortality[122].
Steato-hepatitis: Steato-hepatitis is hypothesised to be the end result of the “two hit 
theory” where the first insult (steatosis) is compounded a second insult in the form of 
reactive oxygen species. Irinotecan is the drug predominantly associated with 
steatohepatitis, with high BMI patients particularly at risk, presumably as result of 
pre-existing steatosis[122]. In terms of its impact on liver surgery, patients with 
steatohepatitis have been shown to have not only more frequent post-operative 
complications, but also significantly increased 90d mortality rate (15% vs 2%for 
patients without steatohepatitis[122].
Chemotherapy-associated hepatic sinusoidal obstruction syndrome: Sinusoidal 
obstruction syndrome (SOS) was first recognised in the context of bone marrow 
transplantation and treatments involving combinations of several cytotoxic drugs[123]. 
In the context of chemotherapy for colorectal liver metastases oxaliplatin is the 
predominant drug associated with SOS, with 78% of patients receiving oxaliplatin 
having evidence of sinusoidal injury[124]. SOS is associated with Increased morbidity 
post liver resection, though not mortality[125].
Chemotherapy duration: As well as the type of agent, there is some evidence that the 
length of chemotherapy course may impact on perioperative complications. In terms 
of minimising chemotherapy associated hepato-toxicity, Karoui et al[125] found that 
patient receiving fewer than 6 chemotherapy cycles experienced significantly fewer 
post liver resection complications than those who had received more than 6 cycles 
(19% vs 54% complication rate) although there was no impact on mortality rates.
In the context of other evidence discussed below, hepatoxicity may influence choice 
of chemotherapeutic agent, for example with a caution in relation to the reported 
increased mortality associated with irinotecan in patients with pre-existing steatosis 
who are potential surgical candidates.
Chemotherapy for patients with unequivocally unresectable disease
The subgroup of patients with liver unresectable metastasis represents a very 
heterogeneous group, and therefore a careful multidisciplinary evaluation of patient 
and tumour’s characteristics as well as treatment toxicities is crucial in the decision-
making process. In this setting, patients may be distinguished into three different 
subgroups: (1) Patients with good performance status but with tumour burden related 
symptomatic disease; (2) Patients with good performance status but without 
symptoms related to tumour burden; and (3) Patients with poor performance status. In 
the first case, the objective of treatment is the tumour shrinkage with the aim of 
symptom control, whereas in the second subgroup the objective is disease control with 
improvement of OS and preservation of quality of life. In the third group, best 
supportive care represents the most appropriate option because active treatment will 
not be tolerated.
Although a comprehensive description of systemic treatment options for metastatic 
disease is beyond the scope of this review, this section provides a summary of the 
current indications for first-line medical treatment in metastatic CRC.
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According to international guidelines[126] chemotherapy plus target agents (anti-
EGFR or anti-vascular endothelial growth factor) provide the best first line treatment 
for patients with appropriate performance status. In particular, doublet therapy based 
on fluoropyrimidines (5-FU/capecitabine) and oxaliplatin or irinotecan 
(FOLFOX/XELOX/FOLFIRI) represents the standard of care in order to improve 
survival[127-129] More recently, triplet chemotherapy with FOLFOXIRI has been 
associated with a further 25% increase in median OS, although at the expense of 
greater toxicity[130,131]. As trials show no difference in the outcomes when using 
oxaliplatin or irinotecan-based doublets, the choice is mainly related to the different 
safety profile[132]. In addition, biological agents could be added to chemotherapy 
according to tumour (RAS mutational status, sidedness) and patient characteristics.
EGFR blockade: The key evidence in favour of EGFR blockade in the context of 
colorectal liver metastases comes from randomised trials demonstrating improved OS 
and progression free survival (PFS) in patients treated with EGFR blockade added to 
conventional chemotherapy compared with chemotherapy alone. Summarising this 
evidence, a meta-analysis of randomised trials showed that combining cetuximab or 
panitumumab to oxaliplatin or irinotecan regimens increased response rates in 
patients with initially inoperable CLM[133]. In terms of the relative efficacy of oxaliplatin 
vs irinotecan based regimens in combination with EGFR blockade, the CELIM study 
comparing the efficacy of FOLFOX + cetuximab to FOLFIRI + cetuximab, showed no 
significant difference in efficacy between the 2 regimens[134]. In a trial comparing triplet 
chemotherapy (FOLFOXIRI) + panitumumab to FOLFOXIRI alone, EGFR blockade 
was associated with improved response rates though no difference in PFS or OS[135].
In terms of the efficacy of EGFR blockade alone, Cetuximab alone was found to be 
less effective alone than in combination with Irinotecan in the BOND study[136].
In terms of patient selection for EGFR based therapy, CRC harbouring mutations in 
KRAS[137] and NRAS[138] genes which result in constitutive activation of the downstream 
signalling cascade have been demonstrated to be insensitive to treatment with anti-
EGFR blockade. Furthermore, some RAS wild type CRC may also prove insensitive to 
EGFR blockade, possibly due to the presence of other mutations in downstream genes, 
including that of BRAF, present in 9% of CRC, and associated with poor prognosis[139], 
or amplification of receptor tyrosine kinase genes[140] or mutations in the EGF receptor 
itself[141]. In addition, there is growing evidence that primary tumour sidedness may 
also affect response to EGFR blockade, with right sided tumours failing to benefit, 
even when RAS wild type, as discussed further below[142].
Anti-angiogenic agents: Bevacizumab is the only anti- vascular endothelial cell 
growth factor agent approved in first line setting for metastatic CRC. Several trials 
have demonstrated that bevacizumab improves overall response rate, PFS and OS 
when added to irinotecan based regimens and PFS when added to oxaliplatin based 
regimens[143,144] regardless of RAS status. Furthermore, a meta-analysis of 6 randomized 
clinical trials assessing bevacizumab in patients with metastatic CRC reported 
improved PFS and OS[145]. In terms of combining bevacizumab with triplet 
chemotherapy, the phase II OLIVIA trial studied the addition of bevacizumab to 
FOLFOX or FOLFOXIRI in patients with initially unresectable liver and demonstrated 
improved PFS, overall response rate and R0 rates in the FOLFOXIRI + bevacizumab 
group[146], with confirmation of these results in the phase III TRIBE trial[147].
Factors influencing choice of targeted therapy: In considering the choice between 
EGFR blockade and antiangiogenic agents in combination with chemotherapy in RAS 
WT patients, evidence is somewhat conflicting.
Whilst the FIRE 3 trial[148] (comparing FOLFIRI plus cetuximab vs FOLFIRI plus 
bevacizumab as first-line treatment for patients with metastatic colorectal cancer), and 
the PEAK trial[149] (comparing FOLFOX plus panitumumab vs FOLFOX plus 
bevacizumab) both reported improved OS in the EGFR blockade group, the CALGB 
80405 trial showed no difference in OS between EGFR blockade and anti-angiogenic 
agents[150].
Combination of EGFR blockade with anti- angiogenic agents was examined in the 
PACCE trial which suggested prohibitive increased toxicity[151], and although this was 
not confirmed in the combination CAIRO 2 study[152], concerns regarding toxicity have 
led to an avoidance of the combination of EGFR blockade with anti-angiogenics.
The choice of which targeted therapy is best added to conventional chemotherapy 
may also be influenced by the sidedness of the primary tumour. It is increasingly 
recognised that right and left sided colon cancers have different biological and clinical 
behaviours which impact on their response to systemic treatment. In a systematic 
review of 6 randomised trials examining treatment regimens for RAS wild type colon 
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cancer, Arnold et al[142] found that right sided tumours had worse prognosis, that EGFR 
blockade benefit was restricted to left sided tumours, that there may be possible 
adverse effect of EGFR blockade to right sided tumours, and that right sided tumours 
may benefit more from anti-angiogenic therapies, thus giving rise to the consideration 
of triplet therapy combined with bevacizumab for right sided tumours.
Novel agents: Novel agents targeting other aspects of known oncogenic pathways 
(Figure 1B) are also in varying stages of assessment. These include multi-kinase 
inhibitors, agents targeting other steps in the EGF receptor signalling pathway, 
antiangiogenic agents, and immune checkpoint inhibitors.
Multi-kinase inhibitors such as regorafenib inhibits a wide range kinases impacting 
on several oncogenic pathways[153], and has shown OS benefit in randomised double 
blind control trials[154,155].
EGFR pathway blockade using EGFR tyrosine kinase inhibition by agents such as 
erlotinib or gefitinib has been associated improved PFS when combined to 
bevacizumab in the DREAM trial[156].
The BRAF mutation, present in 10% of colorectal cancers, and associated with 
aggressive disease and poor prognosis has been targeted by the agent vemurafenib in 
combination with EGFR blockade[157] with marked responses in some case reports[158].
MEK kinase has been targeted by the inhibitor selumetinib with tumour response 
shown in some patients with KRAS mutant colorectal cancers progressing on 
oxaliplatin[159].
The potential for exploiting anti-angiogenic pathway is also under investigation 
with other agents such as famitinib which inhibits multiple receptor tyrosine kinases, 
and monoclonal antibodies targeting the VEGF receptors[160].
Pembrolizumab is an immune checkpoint inhibitor which impacts on cytotoxic 
immune responses. In a phase 2 study mismatch-repair status predicted clinical benefit 
of immune checkpoint blockade with pembrolizumab[115].
Chemotherapy for patients with up-front resectable disease
In patients with up-front resectable colorectal liver metastases, the role of 
chemotherapy has been investigated in both neoadjuvant and adjuvant roles.
Neoadjuvant chemotherapy: In the context of initially resectable liver metastases, 
neoadjuvant chemotherapy may have theoretical advantages or objectives such as 
assessing chemo-responsiveness to inform future treatment strategy, provide tumour 
shrinkage to increase chance of R0 resection, and to eliminate undetectable micro-
metastases. Weighed against these potential advantages are the disadvantages of 
chemotoxicity, and hepatoxicity in particular. In the midst of these conflicting 
principles, 2 randomised trials provide evidence.
The first, the EORTC 40983 trial[161], which compared liver resection alone to 
FOLFOX (6 cycles preop) - liver resection - FOLFOX (6 cycles post op). At 3 years the 
study showed a significantly better 8% higher PFS in the peri-operative chemo group, 
but no difference in OS, and significantly more complications in the chemotherapy 
group (25% vs 16%). Moreover, the long term outcome[162] showed no OS benefit in the 
chemotherapy group. The absence of OS benefit has been attributed to the fact that 
with a sample size of 364, the trial was powered to detect a PFS, but insufficiently 
powered for OS. In comparison, trials such as the MOSAIC trial[163] included a 
relatively large sample size of 2246, and was able to detect a 4.2% OS benefit at 6 years 
of follow-up for patients treated with FOLFOX over those treated with Leucovorin 5-
FU after resected stage III colon cancer.
Thus, despite improved PFS in the peri-operative chemo group, the absence of OS 
survival and the increased complication rate has not led to peri-operative 
chemotherapy being used routinely in patients with initially resectable liver 
metastases. Moreover, in a meta-analysis of 18 studies, neo-adjuvant chemotherapy in 
resectable colorectal liver metastases was not associated with a survival benefit[164].
The evidence for targeted therapies in the perioperative context is, if anything, 
weaker. Primrose et al[165] compared 2 perioperative systemic regimens (FOLFOX – 
surgery - FOLFOX vs cetuximab + FOLFOX – surgery – cetuximab + FOLFOX) in 
patients with initially resectable colorectal liver metastases, and found a significantly 
inferior disease free survival (DFS) in the cetuximab group (20.1 vs 14.5 mo). Although 
some confounding factors have been suggested (possible different baseline 
characteristics between groups, 11% missing outcome data, and more ablations and 
more positive margins in cetuximab group), these findings argue against EGFR 
blockade in patients with upfront resectable liver metastases.
Peri-operative or neoadjuvant bevacizumab in upfront resectable disease has not 
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been investigated.
In practice the use of neoadjuvant chemotherapy in the context of upfront resectable 
CRLM is influenced not only by the evidence above, but also by nuances in individual 
case presentations which blur the boundaries of what is meant by “upfront 
resectable”. Adam et al[166] allude to the concept of patients who may be “technically 
“resectable, but in whom a poor oncological outcome is suspected. A hypothetical 
example is shown in Figure 2. Both patient A (with a single superficial CRLM) and 
patient B (with 10 superficial CRLM) are “technically” resectable, but there would 
likely be consensus amongst MDTs that whilst patient A would best be recommended 
for upfront liver resection, patient B would best be served by neoadjuvant 
chemotherapy in the first instance.
In the context of better defining patients who are technically resectable but may 
have a poor oncological outcome, Fong et al[83] developed a preoperative oncological 
score including five factors: Node-positive disease, disease-free interval from primary 
to metastases < 12 mo, > 1 hepatic lesion, > 5 cm in the highest hepatic lesion diameter 
and carcinoembryonic antigen level > 200 ng/mL. Patients with ≤ 2 criteria showed a 
better outcome, while chemotherapy might be considered in case of patients with ≥ 3 
criteria.
This highlights the heterogeneity of “upfront resectable” patients, and MDTs may 
take additional factors than those included in the Fong score into account in decision 
making, resulting in a “case by case” approach.
Adjuvant chemotherapy: There is no level I evidence for the use of adjuvant therapy 
in patients with resected colorectal liver metastases, However, meta-analysis of 
available trials suggests that there may be a benefit to this approach[167]. Included in 
this meta-analysis are the report from Portier et al[168] who compared Surgery alone vs 
surgery with followed by 6 mo of systemic adjuvant fluorouracil and folinic acid, and 
demonstrated an improved DFS at 5 years of 33.5% for patients in the chemotherapy 
group vs 26.7% for patients in the control group, though no OS survival benefit.
Kim et al[169] compared the outcome of 3 different adjuvant chemotherapy regimens 
(oxaliplatin/ fluoropyrimidine (group I), irinotecan/fluoropyrimidine (group II) and 
fluoropyrimidine alone (group III). Median DFS was 23.4 mo in group I and 
significantly better than the combined other groups, 14.1 mo in group II and 16.3 mo in 
group III (P = 0.03).
The EORTC 40983 trial[161] also provides some evidence of chemotherapy benefit in 
PFS, although it is difficult to establish whether this was attributable to adjuvant 
chemotherapy, as the trial group also received neo-adjuvant treatment.
Thus, in the context of adjuvant chemotherapy for resected colorectal liver 
metastases there is some, though limited, evidence for improved DFS with certain 
agents. As a theoretical consideration, adjuvant treatment allows chemotherapy 
delivery and avoids the increased liver surgery complications associated with neo-
adjuvant chemotherapy.
Conversion and down-sizing chemotherapy for patients with initially unresectable 
disease
The results of downsizing chemotherapy for initially unresectable colorectal liver 
metastases are well established. In a systematic review including 10 studies of 
downsizing systemic chemotherapy and rescue liver surgery for initially unresectable 
CLM, Lam et al[170] reported objective response rate of 64% (range, 43%–79%) of 
patients after systemic chemo-therapy, with 22.5% of patients converted to a resectable 
status and macroscopically curative liver resection overall. For those resected patients, 
median overall survival was 45 (range, 36–60 mo) mo with 19% of patients alive and 
recurrence-free, thus comparing favourably to chemo alone, and to outcomes for 
patients undergoing up-front resectable liver metastases.
Downsizing regimens based on oxaliplatin[171] and irinotecan[172] have achieve similar 
response rates in the range of 50% and rates of liver metastases resection of 33%-40%. 
Moreover, in a randomised controlled trial comparing FOLFIRI and FOLFOX, the two 
regimens had identical response rates (55%) and similar levels of clear margin (R0) 
resections[173]. The triplet combination of folinic acid 5FU, oxaliplatin and irinotecan 
has also been studied, and in randomised trials comparing FOLFOXIRI to FOLIFIRI[130] 
and FOLFIRINOX to FOLFOX or FOLFIRI[174], the triplet combination was associated 
with improved response rates, progression free survival, overall survival, and 
increased resection rates, but at the expense of greater toxicity.
EGFR blockade in downsizing setting: Given the evidence demonstrating the benefit 
of adding EGFR blockade to conventional chemotherapy in the setting of 
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Figure 2  A hypothetical example is shown. A: Patient A (with a single superficial colorectal liver metastases); B: Patient B (with 10 superficial colorectal liver 
metastases).
unequivocally unresectable colorectal liver metastases[133], the potential for such 
combination to maximise conversion of initially unresectable liver metastases has also 
been explored. Thus addition of EGFR blockade to systemic chemotherapy in RAS 
wild type patients was associated with improved conversion to resectability and R0 
rates[175], in comparison to systemic chemotherapy alone. Furthermore, in the CELIM 
trial comparing cetuximab with either FOLFOX or FOLFIRI, both regimens 
demonstrated similar high response rates and increased resectability rates[134].
The impact of adding EGFR blockade to triplet chemotherapy has also been studied 
in The VOLFI trial comparing FOLFOXIRI with panitumumab vs FOLFOXFIRI alone, 
showing improved response rates and resection rates in the panitumumab group[135].
Antiangiogenic therapy in downsizing: Anti-angiogenic therapies have also been 
studied in the downsizing context. Wong et al[176] reported a 40% conversion to 
operability with XELOX and bevacizumab. Similarly, increased resection rates, R0 
rates and PFS were associated with addition of Bevacizumab to triplet chemotherapy 
in the OLIVIA trial[146].
As discussed in the section relating to inoperable colorectal live metastases, the 
choice of addition of EGFR blockade or antiangiogenic therapy is a complex one, and 
is influenced not only by RAS status, but also by primary tumour sidedness[142].
In conclusion, an improvement in OS is clearly demonstrated for patients converted 
to R0 surgery by use of conversion chemotherapy. Radiological response should be 
evaluated 2-3 moly by RECIST criteria, taking into account the radiological pattern of 
response to antiangiogenic agents. Timing of surgery is critical in order to avoid 
overtreatment of lesions which may disappear and to avoid liver toxicity. The benefit 
derived from adjuvant treatment (chemotherapy alone or in association with target 
agents) in patients that received complete resection of liver metastasis after conversion 
therapy is still unclear.
Locoregional intra-arterial therapies
In addition to the systemic agents described above, the option of locoregional 
chemotherapy, delivered intra-arterially by a variety of means also exists. The 
following section describes current knowledge of hepatic arterial infusion (HAI) 
chemotherapy, and trans arterial delivery of irinotecan coated beads (DEBIRI).
Hepatic arterial infusion chemotherapy: The underlying biological rationale for 
considering hepatic arterial infusion chemotherapy is based on the fact that the blood 
supply to colorectal liver metastases is predominantly arterial, and that such infusion 
provides favourable pharmacodynamics allowing high intrahepatic and low systemic 
concentrations of drugs[177]. The potential role of hepatic arterial chemotherapy, via 
surgically or percutaneously placed catheters[178], has been studied in varying contexts, 
including patients with unresectable colorectal liver metastases, but also in 
downsizing and adjuvant scenarios.
In the unresectable CRLM context, although initial reports from randomised trials of 
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HAI[179] suggested survival benefit , the modest increase in survival was not widely 
been felt to justify the quality of life cost brought about by the considerable toxicity 
associated with Floxouridine. However, further studies with newer agents including 
Oxaliplatin HAI, 5FU/leucovorin intravenously (IV)[180], Oxaliplatin + Irinotecan + 5FU 
HAI + cetuximab IV[181] in first or second line settings reported median overall survival 
of 25 to 27 mo, with conversion to operability in 29% and 37% survival at 4 years for 
those who underwent resection. Thus, although the place of HAI remains uncertain in 
the first line setting, these results could form the justification for a randomised trial of 
HAI vs conventional systemic chemotherapy in second line treatment.
In the adjuvant setting one non randomised report[182] studying 2368 consecutive 
patients after complete resection of CLM suggest a potential significant benefit in OS 
for patients receiving HAI with significantly improved median OS 67 mo vs 47 mo 
without HAI (P = 0.001) and 10-year survival (38.0% vs 23.8% without HAI). In terms 
of randomised data, although one randomized trial demonstrated increased disease-
free survival with systemic chemotherapy (5-FU) plus HAI compared to systemic 
chemotherapy alone (37.4 vs 17.2 mo, P < 0.01)[183] , a meta-analysis did not 
demonstrate an improved OS[184].
In summary, HAI has progressed a great deal since the early reports associated with 
prohibitive toxicity, and with improvements in catheter placement options. Non-
randomised results suggest a potential benefit, although this needs confirmation in 
carefully designed trials, some of which are in progress[177,185].
DEBIRI: DEBIRI consists of trans arterial delivery of irinotecan coated beads, 
theoretically allowing slow drug delivery for prolonged antineoplastic effect.
The mechanism of action of DEBIRI[186] presents a paradox in that intra-arterial 
delivery implies a regional effect of the drug, although irinotecan is a prodrug that 
requires activation in healthy liver parenchyma to its active Topo-isomerase 1 
inhibiting metabolite. Animal models suggest that although much lower overall doses 
are given in DEBIRI, drug levels at 24 h are higher in tumour and lower in serum than 
with either intra-arterial or intravenous administration. Further animal model studies 
suggest that beads cause ischaemic embolization in the predominantly arterial 
vascularity of tumours. Although beads alone have little tumour burden reducing 
effect, there is a dose response to DEBIRI beads suggesting that ischaemia and the 
drug act in concert. This is perhaps as a result of ischaemia induced acid pH, at which 
the active form of irinotecan is much more effective, and thus perhaps explaining its 
sparing of neighbouring liver parenchyma where ischaemia is less marked owing to 
the predominant portal circulation.
The clinical experience of DEBIRI was reviewed by Akinwande et al[187] in a 
systematic review including 11 single arm retrospective and prospective phase studies 
and two prospective randomized control trials involving 850 patients. Overall toxicity 
rates were reported at 35% with 10% high grade toxicity, and 2 possible treatment 
related deaths (0.2%). Overall response rate was 56%, in spite of the fact that patients 
referred for DEBIRI typically had undergone at least 2 prior lines of chemotherapy. 
Progression free survival and overall survival was 8.1 mo and 16.8 mo, respectively, 
comparing favourably with comparable cohorts.
Two randomised trials have examined DEBIRI vs conventional chemotherapy. 
Martin et al[188] compared FOLFOX and bevacizumab to FOLFOX, bevacizumab + 
DEBIRI (FOLFOX - DEBIRI), and found that the DEBIRI patients had significantly 
better overall response, and improved median progression-free survival (15.3 mo vs 
7.6 mo). Fiorentini et al[189] compared DEBIRI with systemic FOLFIRI, and found that 
the DEBIRI group had significantly improved OS (OS median 22 and 15 mo 
respectively, P = 0.031), PFS [median 7 vs 4 mo (P = 0.006)], although the study was 
criticized for the absence of Cetuximab in the FOLFIRI arm.
In summary, DEBIRI has been shown to be safe in the treatment of colorectal liver 
metastases and to have promising response rates in the setting of patients who have 
been exposed to multiple prior lines of chemotherapy, with some early randomised 
evidence of favourable results in comparison to systemic chemotherapy. Its ideal role, 
in terms of patient group and optimal context, remains to be determined by future 
trials.
Radiation based therapies for unresectable CRLM
In addition to chemotherapy in all its forms, unresectable CRLM may be treated by 
radiation either by selective internal radiotherapy (SIRT) or stereotactic body 
radiotherapy (SBRT).
Selective internal radiation therapy: The blood supply of metastatic liver tumours is 
Martin J et al. Colorectal liver metastase
WJCO https://www.wjgnet.com 776 October 24, 2020 Volume 11 Issue 10
predominantly arterial, in contrast to that of hepatocytes which is mostly portal 
venous[190,191]. This, together with significant arterial neovascularisation in the tumour 
bed[192], provides the physiological underpinning of SIRT, which achieves tumour 
destruction by delivery of radioactive microspheres via its arterial supply. Ytrium-90, 
which undergoes beta decay, is the most commonly used radionuclide used to label 
microspheres, on account of favourable penetration characteristics: Mean and maximal 
penetration are 2.5 and 10 mm respectively, thus delivering maximal irradiation to the 
tumour whilst sparing surrounding parenchyma[193]. Currently glass and resin-based 
versions of the sphere are commercially available. A newer sphere which employs 
Holmium-166 rather than Ytrium-90 is also available and being evaluated[194].
In the context of colorectal liver metastases, interest in SIRT originated from studies 
done in patients with unresectable liver or liver dominant metastases who had proved 
refractory to conventional chemotherapy. These studies suggested response to SIRT in 
the face of prior chemo refractory status[195,196], and in some reports, significantly 
improved OS in patients who responded to SIRT[197-199].
On the basis of the above and other studies, 3 randomised prospective trials[200-202] 
were carried out to investigate the potential role of SIRT by comparing FOLFOX + 
SIRT vs FOLFOX alone as first-line treatment for mCRC with liver-only or liver-
predominant metastases. The combined results of the 3 trials were reported by Wasan 
et al[203]. The overall findings were that there was no OS survival benefit to the addition 
of SIRT to FOLFOX, but that progression within the liver within the first 12 mo of 
follow-up was significantly lower in the SIRT group.
It was concluded that given the absence of OS survival, SIRT could not be 
recommended as first line treatment for mCRC with liver-only or liver-predominant 
metastases, but that its role in other contexts required investigation. In this perspective 
Gibbs et al[204] reviewed the outcomes of the FOXFIRE trials with respect to primary 
tumour sidedness and found that the median OS for patients with right-sided 
primaries was significantly higher for patients in the SIRT arm compared to the control 
group, and that left sided primary tumour patients did not benefit from SIRT.
In summary, the current role of SIRT is evolving and will doubtless be further 
refined as the results of new trials become available. In the United Kingdom, based on 
a review of current evidence[205], SIRT is commissioned for use in patients with 
unresectable or ablatable colorectal liver metastases who have progressed or are 
refractory to both oxaliplatin-based and irinotecan-based chemotherapy, with five or 
fewer liver tumours, a percentage tumour to liver volume of ≤ 25%, and World Health 
Organisation (WHO) performance status 0-1[206].
Stereotactic body radiation therapy for colorectal liver metastases: The results of 
studies suggesting benefit to local ablative therapies such as RFA[207] in the treatment of 
colorectal liver metastases has prompted investigation of whether similar benefits 
could be achieved by radiotherapy. Stereotactic body radiation therapy offers an 
alternative approach to the treatment of liver metastasis by precise targeted delivery of 
radiation. The potential benefits would be the use of a non-invasive technique, without 
need for general anaesthetic, and perhaps an opportunity of overcoming the 
limitations of ablation such as tumour size restriction, and problems such as heat sink 
effects in tumours situated near vascular structures.
In a systematic review, Petrelli et al[208] analysed the results of a total of 18 studies, 
encompassing 656 patients, with colorectal liver metastases, numbering 1–2 lesions in 
most cases, with a size range of 0.7-11.6 cm in size, the majority having received 
systemic chemotherapy, with a median follow up of two years.
The pooled one and two-year OS were 67.18% and 56.5% respectively, and median 
PFS and OS were 11.5 and 31.5 mo. The pooled one-year and two-year local control 
was 67% and 59.3%. In terms of liver related toxicity, pooled grade 1–2 and grade 3–4 
liver toxicity[209] were 30.7% and 8.7%, with mild nausea and fatigue reported as other 
toxicities. There were 4 cases of liver failure (0.6%), and three treatment related deaths 
(0.004%).
The optimal irradiation dose is likely to be multifactor dependant, but reports 
suggest improved local control rates after increasing biological equivalent dose, with 
local control rates of 90% in patients exposed to higher biologically effective 
dose[210,211], with dose response relation confirmed in a pooled analysis[212]. In terms of 
lesion size limits, although early reports correlate large tumour size (> 3 cm) with 
poorer rates of local control[213], more recent studies report local control in tumours 3-6 
cm as equivalent to that achieved with tumours less than 3 cm by use of higher 
irradiation doses[214].
The interpretation of data relating to the effectiveness of SBRT in the treatment of 
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colorectal liver metastases is difficult for a number of reasons: Firstly the studies are 
subject to case selection bias, and markedly heterogeneous in terms of population and 
techniques: The study populations vary in age and performance status, number and 
size of metastases, median follow-up, subsequent chemotherapy delivery, SBRT 
techniques, and fractionation. Secondly, the absence of randomised trials makes it 
difficult to assess the hypothesised additional benefit that SBRT may bring to optimal 
chemotherapy and existing ablation methods.
In this regard, there is a difficult problem with recruitment to such trials, with 2 
examples of such studies (the French OLIVER trial (NCT03296839) investigating 
chemotherapy +/- SBRT[215], and the Dutch RAS01 trial (NCT01233544)[216] comparing 
systemic chemo + RFA or SBRT) both closed with insufficient recruitment. 
Undoubtedly part of the problem with recruitment in such areas is the fact that both 
patients and clinicians may not perceive equipoise. Furthermore, different techniques 
are often complementary rather than in competition, such that their indication for use 
may be subtly but importantly different. For example, a tumour adjacent to a large 
vein may not be appropriate for ablation because of heat sink effect, but potentially a 
good indication for SBRT.
In summary, the results of SBRT in terms of local control and overall survival are 
hard to ignore, especially as they are achieved in the context of patients who have 
exhausted other treatment options. Although formal comparisons with other 
treatments will be difficult to carry out, ongoing studies to define SBRT technique such 
as irradiation dose and fractionation will likely deliver ongoing improvements in 
outcomes and help to define the niche for SBRT in the armamentarium for treatment of 
colorectal liver metastases.
SECTION 4: SURGICAL MANAGEMENT OF RESECTABLE COLORECTAL 
LIVER METASTASES
Introduction
The success of liver resection for CRLM in achieving long term survival has driven the 
investigation of numerous techniques to increase resection rates. In defining 
‘resectability’, there is distinction to be made between what is technically feasible, and 
what is oncologically sensible. In this regard, clinical, biochemical and 
histopathological factors[79-82] and risk scores such as the Fong score[24] (see section 2) 
have provided some direction in decision making. From the sole perspective of 
technicality however, CRLM may be thought of as resectable provided that clear 
margins are achieved, and that the Future Liver Remnant (FLR) is of sufficient size, 
with adequate arterial supply, portal venous supply, hepatic venous drainage, and 
biliary outflow. The techniques used to increase resectability include downsizing 
chemotherapy (discussed in section 3), portal vein embolization (PVE), Associating 
Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), and the use 
of ablation technology. Surgery may be carried out laparoscopically or open, and in 
selected patients prior to or synchronously with resection of the primary CRC. These 
considerations are discussed in more detail in this section.
Liver resection for CRLM: General considerations
Biopsy of CRLM: Biopsy of suspected CRLM should be avoided. The problem of 
needle track seeding with malignant cells following biopsy of malignant liver lesions is 
well documented in the context of HCC[217]. In terms of this risk in biopsy of CRLM, 
Rodgers et al[218] reported that out of 43 patients who had undergone CRLM biopsy, 7 
(16%) developed needle track seeding[218]. In a similar study Ohlson et al[219] reported a 
needle track seeding rate in 5 (10%) of 51 biopsied patients. Jones et al[220] reported a 
19% rate of needle track seeding and found that following resection of CRLM, biopsied 
patients had a significantly lower 4 year survival, with biopsy being identified as an 
independent predictor of poor survival in regression analysis. These findings, taken 
together with the low percentage (< 2%) of benign lesions resected unnecessarily 
following incorrect radiological diagnosis of a CRLM argue strongly against pre-
operative biopsy of CRLM[221].
Anatomical vs non-anatomical resections: In a systematic review of 2505 patients 
included in 12 studies, Moris et al[222] found that there was no difference between 
anatomical and non-anatomical (parenchymal sparing) hepatectomy in terms of peri-
operative and long term oncological criteria, thus arguing in favour of a parenchymal 
sparing approach whenever appropriate.
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Resection margins: There is consensus that positive margins after resection of CRLM 
remains a negative prognostic factor[223] . Although historical practice suggested a liver 
resection margin of 1cm in resection of CRLM, a Propensity Score Case-Match study 
from Hamady et al[224] showed that 1 mm cancer-free resection margin achieved 33% 5-
year overall disease-free survival, and that additional margin width did not add 
disease-free survival advantage. Moreover, De Haas et al[225] reported that although 
patients with involved (R1) margins experienced more recurrences, the 
contraindication of R1 resection should be revisited in the current era of effective 
chemotherapy because survival was similar, in their study, to that of R0 resection. 
Thus, although R0 resection is doubtless preferable, the necessity of R1 resection for 
lesions near structures that cannot be sacrificed, or for preservation of liver 
parenchyma, may be accepted in selected patients.
Extra-hepatic disease: Whilst a full review of resection of extra-hepatic disease is 
beyond the scope of this review, there is consensus in favour of proceeding with liver 
resection of CRLM in particular scenarios[226,227].
Positive retroperitoneal or coeliac lymphadenopathy is still an absolute 
contraindication to liver resection, but hepatectomy may be carried out in selected 
patients with hepato-duodenal ligament lymphadenopathy, albeit with less good 5 
year survival than for patients without hilar lymphadenopathy[228].
Although studies relating to resection of pulmonary resection should be interpreted 
with caution, because of significant patient selection bias, a Liver Met Survey registry 
study reported that selected patients who had resection of liver and lung metastases 
had similar overall survival to those who had undergone removal of isolated liver 
metastases[229].
In terms of peritoneal disease, current studies suggest that in selected patients, 
cytoreductive surgery in combination with chemotherapy is associated with better 
survival than with chemotherapy alone, but there is controversy regarding the benefit 
of hyperthermic intraperitoneal chemotherapy over systemic chemotherapy[230].
Laparoscopic and robotic liver resection: Laparoscopic liver surgery has increased 
rapidly over the last decade with reports of minor and major liver resections[231,232], 
ALPPS[233] and both paediatric[234] and adult[235] live donor liver donation.
The international consensus conference on laparoscopic liver resection[236] 
established a range of recommendations and guidelines with an imperative that the 
innovators in this field deliver high quality evidence to validate its introduction into 
standard practice, and randomised clinical trials comparing laparoscopic and open 
liver resection followed as a result[237,238]. The ORANGE II trial[239] closed prematurely 
after failing to recruit. The OSLO COMET trial[237] compared laparoscopic with open 
parenchymal sparing liver resection for minor liver resections in 280 patients. The trial 
demonstrated a significant reduction in 30 d complications with the laparoscopic 
approach and a shorter hospital stay of 3 compared to 4 d. There was no difference in 
resection margin status or overall survival between groups. The significantly increased 
initial operative costs of the laparoscopic approach were offset by the shorter stays in 
recovery and hospital stay resulting in no overall difference between the two groups.
Thus the evidence from OSLO COMET trial, case series and cohort studies suggest 
that laparoscopic liver surgery is not inferior to open liver resection in terms of 
operative mortality, margin negativity and overall survival for both minor and major 
resections. Furthermore, there may be benefits in terms of reduced length of stay, 
reduced post-operative pain, and a reduction in the need for blood transfusion. At this 
time there remains a significant heterogeneity in adoption of not only laparoscopic but 
also robotic[239] liver surgery and it is appropriate that these evolving techniques 
should be performed in high volume centres with expertise in advanced minimally 
invasive procedures[240].
Liver function and volume assessment
Liver failure after resection has mortality of up to 80%[241], and hence there is much 
interest in the assessment of liver function, in particular the prediction of function in 
the future remnant liver (FRL), with a view to maximising safety following liver 
resection.
Although global clinical liver function assessment systems exist, such as the Childs 
Pugh score for assessment of liver function in the presence of chronic liver disease, and 
the MELD score for risk stratification of patients with end-stage liver disease awaiting 
transplantation, neither the Childs Pugh score[242] or MELD score[243] have proved useful 
in the context of liver resection in patients without underlying liver disease. Moreover, 
these scoring systems apply to the whole liver and cannot be used to predict function 
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of a defined part of the liver such as the FRL.
Modern imaging software allows the accurate calculation of volumes of defined 
parts of the liver, such that the volume of the FRL may be assessed either as an 
absolute value or as a fraction of the whole liver. Whilst volume alone may be helpful 
in patients with completely healthy liver, in which case a minimum FRL of 25% has 
been advocated, in cases where liver parenchyma is suboptimal volume may not 
correlate with function[244,245], particularly in patients with steatosis, chemotherapy 
associated liver injury, or after PVE or ALPS. For those on the limit of threshold, 
decision making is difficult, and thus the shortcoming of purely volumetric 
assessments has prompted the investigation of dynamic liver function tests, which are 
discussed below.
Indocyanine Green: Indocyanine Green (ICG) is a tricarbocyanine dye that binds to 
albumin and is distributed evenly in the blood within minutes of intravenous 
injection. ICG is taken up by the liver and is excreted in bile without conjugation[246].
Whilst having some value in predicting post op liver failure an death in the context 
of HCC resection in cirrhotic patients[247], this was not the case in resection of colorectal 
liver metastases in chemotherapy affected livers[248]. Moreover, ICG clearance provides 
a global assessment of liver function and does not offer the possibility of assessing 
parts of the liver, in particular the future remnant liver left in situ after a resection. 
Although calculating fractional ICG excretion has been reported[249] this assumes 
homogenous liver function, and in this regard, Hepato-biliary scintigraphy offers 
potential opportunities.
Hepatobiliary scintigraphy: Hepato-biliary scintigraphy (HBS) uses a gamma camera 
detection system in combination with cross-sectional imaging to quantitatively assess 
hepatic processing of a labelled molecule, both globally and/ or regionally in the liver, 
thus allowing future remnant liver functional assessment. Two main labelled 
molecules, Galactosyl human Serum Albumin and iminodiacetic acid (IDA) 
derivatives have been reported on most widely. (1) Technetium-99 m galactosyl 
human serum albumin scintigraphy: Galactosyl human Serum Albumin is exclusively 
taken up in the liver by an active transport mechanism on the sinusoidal surface of 
hepatocytes, and is thereafter degraded in lysosomes without biliary excretion, thus 
offering the advantage of not being affected by high bilirubin concentrations. Its use 
has been developed significantly in Japan where it is reported as a useful technique in 
the prediction of post liver resection liver failure[250], but little used outside Japan 
owing to availability; (2) Hepatobiliary scintigraphy using IDA derivatives: 
Technitium labelled IDA derivatives, of which Mebrofenin is the most effective 
because of its high hepatic specificity and low competitive displacement by bilirubin, 
are taken up in the liver and then excreted into bile by active transport mechanisms. 
Protocols reviewed by Rassam et al[251] allow the calculation of hepatic extraction of 
Tc99 Mebrofenin as a percentage of total dose per minute, adjusted for body surface 
area. Single-photon emission CT-computed tomography (SPECT-CT) is combined with 
the extraction data to provide values for total liver or future remnant liver. Early 
studies determined that pre-operative values calculated for future remnant liver 
function correlated well with actual future remnant function measured post 
operative[244], thus suggesting the technique as a valuable pre-operative function 
assessment of the FLR; (3) Use in predicting post hepatectomy liver failure: Dinant 
et al[245] studied 46 patients with mixed tumour histology requiring liver resection, with 
and without underlying liver parenchymal disease. Patients with uptake above 
2.5%/min/m2 had a 3% chance of liver failure in comparison to those with uptake 
below 2.5%/min/m2 who had a 56% chance of liver failure. Moreover, patients with 
uptake above 2.2%/min/m2 had a 3% chance of mortality whilst those with uptake 
below 2.2%/min/m2 had a 50% chance of liver failure. The volume of the future 
remnant was not significantly associated with any of the outcome parameters. 
Similarly, in a review of 55 high-risk patients undergoing major liver resection, de 
Graaf et al[252] identified patients who developed postoperative liver failure. Thus, 
patients with values above and below 2.69%/min/m2 had 2.4% and 57% chance of 
developing liver failure respectively. Likewise, Chapelle et al[253] studied 88 patients 
undergoing liver resection and found that post op liver failure was strongly associated 
with FRL- F but not future remnant volume, and that no liver failure mortality was 
observed in patients with FRL-F of above 2.3%/min/m2; and (4) Tc 99 Mebrofenin use 
in post PVE situation and ALPPS: Cieslak et al[254] studied 163 patients undergoing liver 
resection whose need for PVE was based on FRL-F by Tc99Mebrofenin extraction, with 
a cut off value of 2.7%/min/m2. The authors noted that 8/29 patients required PVE 
based on low HBS values in spite of satisfactory volume assessments, thus suggesting 
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that HBS may have prevented post op liver failure in those patients. Similarly, 
Chapelle et al[255] used a cut off value of 2.3%/min/m2 as cut off for proceeding to PVE 
and found a lower incidence of post op liver failure than observed in a historical 
control group. Cieslak et al[256] identified Mebrofenin hepato-biliary scintigraphy 
parameters which identified non response to PVE at an earlier stage than conventional 
volume assessment 6 weeks post PVE, thus potentially allowing early selection of 
patients who may require ALPS. A significant concern with ALPS is the incidence of 
post op liver failure after the second stage, raising the impression that liver volume 
does not correlate well with function in the post ALPS setting, perhaps due to 
functional immaturity of rapidly proliferating hepatocytes. Supporting this notion, in 
the second stage of ALPS, Olthof et al[257] found that liver volume growth was out of 
proportion with the increase in function as assessed by HBS, and suggest the use of 
HBS FLR assessment in this setting rather than just volume. In conclusion, in the 
context of liver resection for colorectal liver metastases, assessment of the FLR is 
crucially important to avoid PHLF. Increasing evidence supports the role of hepato-
biliary scintigraphy, as a technique which offer a specific functional assessment 
applicable to defined regions of the liver. Further confirmation and definition of the 
potential should be forthcoming with the results of a large multicentre prospective 
trial[258].
Downsizing chemotherapy for conversion of initially inoperable CRLM
The role of downsizing chemotherapy for initially unresectable colorectal liver 
metastases (discussed in more detail in section 3) is well established, with a systematic 
review by Lam et al[170] and others[259] reporting a response rate of 64%, with 22.5% of 
patients converted to curative liver resection overall.
The paradox of this chemotherapeutic success is the phenomenon of the 
disappearing metastasis, which presents a problem for the surgical team.
Disappearing metastasis: Radiologically disappearing metastasis reported with 
frequencies ranging from 6%[260], 24%[261], and up to 37%[262], Perhaps reflecting 
differences in imaging practice between centres and also different chemotherapy 
regimens. The percentage of patients in whom all CLM disappear radiologically is low 
(0%-6%).
Metastasis disappearance is usually a radiological phenomenon rather than a 
biological one: In a systematic review of 11 studies describing disappearing colorectal 
live metastases, it was found that in 65% of cases of “disappeared metastasis”, a lesion 
was found at laparotomy. Moreover, of the 35% of lesions not found at laparotomy 
and therefore not resected, 80% regrew, at site of radiologically disappeared 
metastasis[263]. Furthermore, there is not a good correlation with complete radiological 
response and complete pathological response: In Adam et al[264] study, complete 
pathological response was seen in 4% of patients undergoing liver resection for CLM, 
but none of these had complete radiological response.
Thus in terms of management of the disappearing liver metastasis the guiding 
principle is that viable tumour is present at the lesion site in the vast majority of cases, 
and therefore resecting the target lesion remains the objective. This may be achieved 
by resecting remnant lesions found at laparotomy visually, by palpation or intra-
operative ultrasound. For lesions which are undetectable at laparotomy, a “territorial” 
resection, encompassing the lesion by reference to fixed landmarks, is sometimes 
possible. The use of 3D augmented reality imaging software may help in this regard in 
the future[265].
Some groups have investigated the pre-operative marking of CRLM with Fiducia 
labels. In a study from Kepenekian et al[266] 76 metastases were marked of which 23 
disappeared with preoperative chemotherapy. Four complications were associated 
with marking: Two intrahepatic haematomas, one fiducial migration and one 
misplacement. After a median follow-up of 47.7 mo, no needle-track seeding was 
noted. Four disappearing CRLM were resected, with two local recurrences, and other 
missing lesions were treated with thermoablation. Thus Fiducia label placement 
presents an option in the management of disappearing CRLM, although concerns 
regarding selection of which CRLM to mark, procedural complications, and needle 
track seeding persist.
In the absence of the above strategies, close surveillance of the target area is the 
default. In future, such lesions may be targeted by image guided stereo-tactic ablation 
of the disappeared metastasis site.
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Portal vein embolization
Portal vein embolization has been credited to various authors[267-269], but most notably 
to Makuuchi et al[270] and Kinoshita et al[271] both of whom reported the use of pre-
operative PVE to induce hypertrophy prior to liver resection in the 1980s, on the 
background of prior reports of portal ligation as part of two-stage extended 
hepatectomies[268]. PVE embolization causes atrophy of the ipsilateral liver segments 
and a compensatory hypertrophy of the FRL. Assessment of the adequacy of 
hypertrophy of the FRL remains challenging. Functional liver assessment is well 
established within Japanese centres[269] but morphological changes in liver volume 
using CT volumetry as an assessment of hypertrophy remains the mainstay of 
assessment in many units. When performed, function assessment has traditionally 
been assessed using indocyanine green clearance however, more recently 99Tc-labelled 
Mebofenin Hepatobiliary scintigraphy and 99Tc-galactosyl-human serum albumin 
scintigraphy have been introduced as discussed above.
A systematic review of PVE reported a major complication rate resulting in non-
resectability of 0.4% and a mortality rate of 0.1% however, complications in the 
published literature are likely under reported. Moreover, detailed descriptions of 
reasons for failure to progress to curative liver resection are frequently lacking in 
published literature. A systematic review of published cohort series reports an overall 
failure to proceed to curative liver resection following PVE of 18.7%. The majority of 
these failures to proceed were due to progression of liver disease (14.2%) and failure to 
induce sufficient hypertrophy of the FRL (2.8%). The mean time between PVE and 
liver resection was 36.9 d[268].
The borderline resectability of tumours that necessitate PVE to enable curative 
resection, combined with concerns regarding the effect of the changes to the liver 
parenchymal metabolism, gene expression and the microenvironment on tumour 
growth post-PVE have led some authors to examine the use of chemotherapy during 
the interval between PVE and resection in an effort to control tumour growth. Cohort 
series have suggested that continuation of chemotherapy during the interval between 
PVE and resection does not change hypertrophy of the FLR[272-274]. Some cohort studies 
have examined the different responses of metastatic disease to neoadjuvant 
chemotherapy and used this to stratify patients into “slow” and “fast” 
responders[273,275]. A cohort series has demonstrated subsequent discordant tumour 
behaviour following PVE between these groups with “slow” responders more likely to 
demonstrate progression of tumour growth with an accompanying increased risk of 
failing to progress to curative liver resection[273].
PVE remains an important tool in the armamentarium for management of patients 
with otherwise unresectable colorectal liver metastases where the FLR would 
otherwise be insufficient following resection. Despite promising reports from cohort 
studies, the published literature remains incomplete and frequently lacks detailed 
descriptions of complications or technical or clinical failure. Moreover, in the most 
recent systematic review colorectal metastasis comprised 39.6% of the patients and this 
heterogeneity limits translation of findings to clinical practice[268].
Two-staged hepatectomy
The concept of the “two-staged hepatectomy” was introduced by Adam et al[276], as a 
technique that could be applied to approximately 4% of patients with conventionally 
irresectable metastases to make them eligible for liver resection with curative intent. 
This approach involved a combination of systemic chemotherapy to downstage 
tumours, with or without PVE, with subsequent planned staged operations that 
permitted curative resection of large tumour burden that would otherwise have been 
considered unresectable. The interval between operations enabled hypertrophy of the 
remnant liver to theoretically reduce the chance of liver insufficiency and patients 
would receive chemotherapy during the interval between operations in an effort to 
control tumour growth. The reported results from this small early cohort 
demonstrated a similar risk of failure to proceed second stage operation when 
compared to PVE, of 19% (3/16). 54% (7/13) developed recurrent disease after 
completion of the second stage and the median survival was 31 mo from the second 
hepatectomy[276]. In current practice, the term, “two-staged hepatectomy” as reported 
by Adam et al[276] is used less and considered as part of the multimodal approach which 
has become a mainstay of current practice.
Associating liver partition and portal vein ligation for staged hepatectomy
The development of ALPPS was the result of an unplanned intraoperative decision by 
Dr Schlitt from Regensburg, Germany. Motivated by a concern for inadequate FLR 
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during a planned extended right hemihepatectomy, a decision was made to perform a 
hepaticojejunostomy on to the left hepatic duct. In order to do so, liver parenchyma 
along the falciform ligament was divided, thus devascularising segment IV, and the 
right portal vein was ligated with the hope of causing hypertrophy of the remnant 
segments II and III. Post-operatively, rapid hypertrophy was observed within 8 d and 
resection of the in situ diseased hemiliver was completed[277].
The combination of portal vein ligation, inflammatory injury and the absence of 
cross portal circulation due to the parenchymal transection has been proposed as the 
mechanism for the observed more rapid hypertrophy compared to PVE alone.
Despite the enthusiasm for this novel technique, the first case series reported a 12% 
mortality and significant morbidity[278]. This was in excess of the mortality and 
morbidity of standard practice with a PVE and two staged approach. The rapid 
introduction of ALPPS to surgical practice with limited scientific rigor has been 
heavily criticised[278], leading to attempts to rationalise its use[278,279]. The LIGRO trial 
was a randomised control trial comparing ALPPS with two staged hepatectomy with 
PVE[280]. This demonstrated a significant increase in the primary endpoint of resection 
rates (92% vs 57%) with ALPPS without a significant increase in 30 or 90d mortality 
between groups. The rate of inadequate hypertrophy in the two stage hepatectomy 
group was higher in the trial than that reported in cohort series and salvage ALPPS 
was performed in 24%, however, 90d mortality in both groups remained high (TSH 
6.1% vs ALPPS 8.3%)[280].
Advocates for ALPPS suggest that the rate of completion of the second stage is 
higher with ALPPS compared to the more established two stage approach with PVE. 
However, this is likely at the expense of a higher peri-operative mortality[281]. More 
recent case series have suggested that with modifications to the original technique 
such as; prolonging the interval between operations, performing a more limited or 
laparoscopic parenchymal transection[282], and the use of the ALPPS risk score[283] the 
peri-operative mortality can be substantially reduced[284].
Opponents highlight that this remains an experimental, unproven technique that 
carries a mortality considerably in excess of the 1%-2% mortality observed in high 
volume units for liver resections following PVE[278] and therefore it should be reserved 
for highly selected cases such as those considered to be high risk of tumour escape 
with PVE or as a salvage technique where PVE has failed to produce sufficient FLR 
hypertrophy. The exact role of ALPPS in the surgical armamentarium remains a 
matter of debate[284].
Ablation techniques for CRLM
The observation of long term survival after resection of colorectal liver metastases, and 
evidence suggesting that locoregional resection is oncologically equivalent to major 
anatomical resection[222] has prompted interest in minimally invasive ablative 
techniques which might achieve similar results to non-anatomical resection with less 
morbidity. Radiofrequency ablation and microwave ablation (MWA) have been 
investigated in the context of a variety of liver tumours including colorectal liver 
metastases.
Radiofrequency ablation: RFA delivers alternating electrical current to cause ionic 
agitation, with the resulting heat generation causing denaturation and coagulation of 
the targeted tissue[285].
The benefit of radiofrequency ablation over systemic chemotherapy alone was 
suggested by the European Organisation for Research and Treatment of Cancer 40004 
CLOCC trial (ClinicalTrials. gov, No. NCT00043004) comparing systemic 
chemotherapy alone to chemotherapy combined with RFA +/- resection for patients 
with inoperable CRLM, which showed a significantly improved progression-free 
survival for patients treated with RFA in the initial analysis[286] and at 9.7 years of 
median follow up[207].
Whilst this randomised trial provides grounds for a genuine benefit of RFA over 
chemotherapy alone, comparing the effectiveness of RFA to that of liver resection is 
difficult, since RFA for CRLM is currently often used in situations where liver 
resection is not deemed appropriate as a result of unfavourable disease factors or 
patient comorbidities. In this context, the absence of randomised data makes 
comparisons of RFA to liver resection subject to a major confounder with an adverse 
bias against RFA.
Meta-analyses have nevertheless assessed the efficacy of RFA in comparison to liver 
resection.
In their 2012 meta-analysis, Weng et al[287] acknowledged the confounding factors 
above, but reported that liver resection was significantly superior to RFA in 3 and 5 
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year overall and disease free survival. Postoperative morbidity was higher in liver 
resection, but no significant difference was found in mortality between liver resection 
and RFA. In a subsequent meta-analysis, Van Amerongen et al[288] reported similar 
findings. In the most recent systematic review of 18 studies and 2667 patients[289]. Kron 
et al[289] reported that in 8/18 studies liver resection patients had significantly higher 
overall survival and disease-free survival, as well as lower local recurrence (LR) rates 
than RFA treated patients.
Based on HCC results where outcomes for lesions less than 5 cm were oncologically 
equivalent to resection, and achieved with less morbidity[290], it was hypothesised that 
RFA may have a particular role in the treatment of small colorectal liver metastases. 
Berber et al[291] reported that tumor size (> 3 cm), ablation margin, and proximity to 
hepatic vessels > 4 mm were found to be independent predictors of LR local 
recurrence after RFA. Hur et al[292] and Ko et al[293] reported similar findings and 
suggested that for colorectal liver metastases < 3 cm, resection and RFA had similar 
oncological and local recurrence outcome, but that RFA was less morbid.
However, in contrast to these studies, subgroup analysis from the systemic reviews 
above does not support idea that CLRM < 3 cm allows results equivalent to resection: 
Weng et al[287] showed poorer OS for lesions < 3 cm treated with RFA compared to 
resection. In Van Amerongen’s et al[288] study, subgroup analysis looking exclusively at 
solitary lesions and lesions of less than 3 cm found that in both cases, there was a 
significantly higher rate of local recurrence in the RFA group (solitary lesions OR = 
7.68, P = 0.001 , and lesions < 3 cm, OR = 8.75, P = 0.001). In Kron’s et al[289] systematic 
review, 4 studies provided evidence comparing RFA to resection for lesions < 3 cm. 
Two of the four studies reported worse OS and higher local recurrence for RFA than 
liver resection[294,295], but the other 2 studies[292,293] found no OS or LR difference between 
RFA and liver resection.
Thus, the literature provides conflicting results, raising the question of whether 
other factors within the group of patients with solitary lesions < 3 cm may account for 
these differing conclusions, including technical and operator factors. In addition, 
historical case series data may not reflect modifications and technical advancements in 
tumour ablation such as better lesion targeting due to the advent of navigation 
systems and appreciation of the importance of ablation zone validation. For example, 
there is evidence that open RFA has lower recurrence rates than percutaneous 
RFA[296-299]. In addition, operator learning curve is reported to impact on outcome[298]. 
Also, operator training may be relevant. In their meta-analysis, Kron et al[289] point out 
that the clinician carrying out the RFA are surgeons and radiologists in 11% and 33% 
of studies respectively, with no specified practitioner in 56% of studies, raising another 
potential confounding factor.
In conclusion, there is randomised evidence showing a benefit for RFA over 
chemotherapy alone. On the subject of RFA vs liver resection, none of the available 
evidence is randomised, and significantly confounded by patient selection, with 
patients undergoing RFA typically having adverse disease characteristics and other 
additional non cancer related comorbidities. In this light, the finding of worse survival 
outcomes for RFA patients is not surprising, but difficult to interpret. In terms of local 
recurrence rates, the role of RFA in colorectal liver metastases < 3 cm remains 
controversial, with conflicting reports. Whilst such controversy may be settled by 
randomised trials, in practice this may prove difficult to achieve. The LAVA trial[300] 
closed due to insufficient recruitment, perhaps due to the perception of non-equipoise 
on the part of both clinicians and patients. The COLLISION trial[301] and HELARC trial 
(Trial ID NCT02886104)[302] are currently in progress.
Microwave ablation: MWA produces tissue destruction as a result of heat generated 
by electromagnetic waves. The theoretical advantages of MWA are faster and greater 
heat generation than in RFA, penetration through tissues with low conductivity and 
less heat sink effect[303] in instances of tumours near blood vessels.
In terms of the efficacy of MWA in comparison to chemotherapy alone, no 
randomised studies have been carried out.
In considering MWA vs liver resection, a small RCT including a total of 30 patients 
with multiple metastatic colorectal liver metastases, Shibata et al[304] randomised 
patients to liver resection or MWA, and found equivalent results in OS or DFS at 3 
years for both treatment modalities.
In terms of comparing of RFA vs MWA, Although a metanalysis by Huo et al[305] 
found MW ablation and RF ablation had similar 1 and 5-year overall survival, disease-
free survival, local recurrence rate, and adverse events overall for a variety of tumour 
types including mostly HCC, the studies that related specifically to CLRM suggested a 
lower local recurrence for MWA. Thus Correa et al[306], in a matched cohort analysis 
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showed patients in the MWA group had lower ablation-site recurrence rates (6% vs 
20%; P < 0.01), and similar results were reported by Liu et al[307]. However, the evidence 
is not unanimous, with some studies finding no difference in local recurrence rates 
between RFA and MWA[307].
Some studies have examined potential differences in tissue effects between MWA 
and RFA, and have found less heat sink for MWA[307] in treating lesions near blood 
vessels, though more complications[308] for peribiliary lesions.
In conclusion, the confounding factors relating to patient selection that make the 
RFA studies difficult to interpret apply equally to MWA, with the additional fact that 
there is generally less data for MWA than RFA. No randomised studies comparing 
MWA to RFA exist, and it may be that the two techniques have complementary rather 
than competing roles given the suggestion of slightly different tissue consequences in 
relation to tumours near blood vessels and bile ducts
Management of synchronous CRLM
Introduction: The scenario of synchronous operable CRLM presents another dilemma 
in opening the options of carrying out liver resection prior to, or synchronously with, 
the primary CRC. The section below discusses the evidence relating to synchronous 
and liver first surgery and is followed by a section on the various scenarios where 
these options may be considered.
Simultaneous liver and colon surgery: The reported experience of a number of 
studies analysing the outcome of simultaneous resection of a primary colorectal 
tumour and liver metastases has allowed some guidance of when this approach is 
appropriate. In a retrospective multicentre study, Reddy et al[309] analysed the outcomes 
of 610 patients who underwent simultaneous (n = 135) or staged (n = 475) resections. 
Combined hospital stay was lower after simultaneous resections (median 8.5 vs 14 d, P 
< 0.0001). Mortality and severe morbidity were similar after simultaneous colorectal 
resection and minor hepatectomy compared with isolated minor hepatectomy. For 
major hepatectomy (defined as resection of at least three segments) however, 
simultaneous colorectal resection increased mortality (8.3% vs 1.4%, P < 0.05) and 
severe morbidity (36.1% vs 15.1%, P < 0.05). Moreover, combined severe morbidity 
after staged resections was lower compared to simultaneous resections (36.1% vs 
17.6%, P = 0.05). Severe morbidity experienced by patients undergoing combined 
resection included hepatic failure, intestinal anastomotic leaks, fascial dehiscence, 
intra-abdominal abscesses, isolated and multiple organ failure, aspiration, and 
pulmonary embolism. Consistent with these conclusions, Jones et al[310] reported that 
the rate of major complications was higher in patients undergoing simultaneous 
resection.
In a single centre retrospective study, De Haas et al[311] reported significantly worse 
progression free survival in the simultaneous surgery group, but also noted that the 
staged surgery group had received significantly more chemotherapy, highlighting the 
difficulty in comparisons in such studies. Similar interpretation questions were raised 
in a large population study[312] involving 442 and 776 patients undergoing 
simultaneous and staged resections respectively. The simultaneous resection group 
had a worse median overall survival, but also had received significantly less 
chemotherapy.
In a recent meta-analysis involving 32 studies[313], it appeared that the messages from 
earlier studies relating to avoiding major hepatectomy in the context of simultaneous 
resections was heeded. In this analysis, the synchronous resection group were found to 
have a smaller proportion of bilobar disease and underwent less major resections. 
Consequently, there was no difference between the synchronous and staged resection 
groups in terms of major morbidity and overall survival.
In conclusion, although interpretation of outcomes is difficult because of patient 
group heterogeneity, the consistent message from available studies is that 
simultaneous colon and liver resection can be performed safely in selected patients. 
Specifically, this excludes liver resections involving 3 or more segments.
Liver-first surgery: The concept of carrying out liver-first surgery in the context of 
synchronous colorectal liver metastases was first reported by Mentha et al[314]. The 
scenarios where liver first surgery has been advocated include: (1) Following 
downsizing of initially unresectable liver metastases with an asymptomatic primary 
tumour in situ, when it is deemed that there is potentially a limited time window for 
successful liver resection; (2) In the situation of synchronous operable primary and 
colorectal liver metastases where the colorectal liver metastases are, by virtue of their 
size or site, deemed most threatening and may become inoperable during time taken 
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to complete a primary first treatment plan; and (3) In the specific instance of 
synchronous rectal cancer and liver metastases, where the significant time interval 
between irradiation of the primary tumour and its resection (3 mo window after long 
course irradiation) provides an opportunity for metastases to be resected substantially 
sooner than would be achieved if waiting till after resection of the primary.
Since Mentha’s original report, other studies series have been contributed such as 
that from Brouquet et al[315] reporting 156 consecutive patients with synchronous 
resectable CLM of which 72 patients underwent primary-first surgery, 43 combined, 
and 27 liver-first strategies, with no difference in morbidity, mortality of long term 
outcome between the groups.
These studies exemplify the problems of interpretation in this area: The numbers of 
patients reported on by individual centres are inevitably limited, and the patients are 
inevitably selected for their most appropriate treatment strategy, thus introducing a 
selection bias in any comparisons between groups.
Although a number of systematic reviews and meta-analyses have since been 
written, and thus allowed a greater numbers of patient cases to be studied, the issue of 
selection bias remains.
Thus, in a report from the Livermet survey, Andres et al[316] reported in a total of 787 
patients including 58 who underwent liver first surgery. The liver first group included 
more rectal cancer, neoadjuvant rectal radiotherapy, and underwent more 
chemotherapy, but overall survival and disease-free survival were similar in both 
groups.
In their systematic review, Jegatheeswaran et al[317] reported on 4 studies in which 
patients underwent neoadjuvant chemotherapy first, then liver resection, then 
resection of the primary tumour. 74% completed the entire treatment protocol. 79% 
proceeded to liver resection, with disease progression on chemotherapy being the 
principle reason for not undergoing hepatectomy. In a further systematic review, Lam 
et al[318] reported very similar findings and conclusions.
In Network meta-analysis reviews, Kelly et al[319] and Gavriilidis et al[313] reviewed 18 
studies and 32 studies respectively and found no significant differences in long-term 
survival and major morbidity were found between the surgical approaches.
In conclusion there are no randomised trials comparing liver-first versus primary-
first surgery, and the highly specific nature of individual patient presentation in this 
context is such that it seems very unlikely that such a trial would be feasible. 
Nevertheless, in selected patients, the liver first approach results in short- and long-
term outcomes that are similar to those achieved when the primary tumour is resected 
first.
Synchronous liver metastases management scenarios: The definition of synchronous 
has not been uniform in existing studies, with some authors including only metastases 
diagnosed at the time of or before diagnosis of the primary tumour, whilst other 
include metastases diagnosed up to 3 or even 6 mo after diagnosis of the primary. 
Based on prognostic outcomes, the EGOSLIM consensus group suggested a 
terminology of synchronous liver metastases (detected at or before diagnosis of the 
primary tumour), Early metachronous metastases (detected within 12 mo after 
diagnosis or surgery of the primary) and Late metachronous metastases (detected 
more than 12 mo after diagnosis or surgery of the primary)[320].
One significant aspect of synchronous presentation of primary tumour and liver 
metastases is the dilemma of which disease site should be treated first, or whether 
systemic chemotherapy should be the initial treatment. The conventional order of 
primary resection followed by liver resection, dictated by chronology in the 
metachronous situation, may not be the most appropriate in synchronous 
presentation.
In practice, the order of treatment is partly dictated by the constraints of the clinical 
presentation which may be summarised in Figure 3 according to primary 
symptomatology and liver disease resectability. (1) Asymptomatic primary and 
unequivocally unresectable liver metastases. In this scenario there is consensus to treat 
with up front chemotherapy, with a range of systemic chemotherapy agents combined 
with EGFR blockade and anti-angiogenic agents, guided by principles as described in 
the section on unresectable metachronous liver metastases, with the intention of 
achieving maximal response, survival, and perhaps in some cases conversion to a 
resectable scenario for the liver metastases. For those patients who are converted to 
operability, liver first surgery may be considered over colon first. In the context of 
downstaged liver metastases, simultaneous liver and colon resection should be 
perhaps be avoided on the strength of Liver Met Survey data showing 5-year survival 
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Figure 3  Management options in synchronous colorectal cancer and colorectal liver metastases, according to presentation criteria. CRC: 
Colorectal cancer; CRLM: Colorectal liver metastases.
rates were 42% for liver first approach compared with 33% for colon first surgery and 
28% for one-stage surgery[320]; (2) Symptomatic primary and unequivocally 
unresectable liver metastases. In this instance, the objective is to deal with symptoms 
from the primary, and thereafter offer optimal systemic chemotherapy. However, the 
differing possible scenarios and lack of evidence leaves much freedom for a pragmatic 
approach based on diverse clinical circumstances with symptomatology in relation to 
bleeding, obstruction or perforation. Bleeding may respond to systemic chemotherapy 
and may be managed by blood transfusion, thus avoiding the need for surgery to the 
primary tumour. Perforation will usually mandate primary resection unless an entirely 
palliative approach is appropriate. Obstruction may require resection of the primary 
tumour, though the options of proximal stoma and stenting may also be appropriate, 
with relative merits of each outside the scope of this review. Once primary symptoms 
have been addressed, systemic chemotherapy is indicated with the aim of maximising 
survival and conversion of liver metastases to an operable scenario, once again guided 
by principles as described in the section on unresectable metachronous liver 
metastases; (3) Asymptomatic primary and resectable liver metastases. This scenario is 
perhaps the one that gives rise to most discussion and controversy. Although the 
EGOSLIM consensus group recommended systemic chemotherapy first for this 
scenario, there was not unanimity in this recommendation, and it was pointed out that 
evidence for such a recommendation was lacking[321]. The only randomised evidence in 
this area comes from the EORTC 40983 trial[161], comparing surgery alone to 
FOLFOX–surgery-FOLFOX, which showed an improved DFS in the peri-operative 
chemotherapy group, though no OS advantage in the early or long term[162]. However, 
the experimental group received both neoadjuvant and adjuvant chemo, such that it is 
difficult to state whether any survival advantage was associated with neoadjuvant 
treatment, adjuvant, or both. Arguing against the value of neoadjuvant treatment, 
Adam et al[321] showed no benefit associated with neoadjuvant treatment prior to 
resection of solitary metachronous liver metastases[321]. Although providing some 
evidence, both Adam’s study and the EORTC trial are nevertheless not directly 
applicable to the scenario of synchronous liver metastases, as almost 2/3 of the liver 
metastases in the EORTC trial were metachronous, and Adam’s study relates 
exclusively to metachronous liver metastases. In a retrospective report Bonney et al[322] 
studied 1301 patients with synchronous liver metastases, and compared those who 
received neoadjuvant chemotherapy prior to liver resection to those who underwent 
liver surgery without neoadjuvant chemotherapy. Neoadjuvant chemotherapy did not 
affect outcome and was not associated with any survival advantage. Of note, the 
surgery up front group had a greater number of solitary metastases, and therefore a 
separate analysis was undertaken to take this into account. The authors found that for 
patients with solitary CRLM, neither neoadjuvant nor adjuvant chemotherapy was 
associated with a survival advantage. In contrast, for patients with multiple liver 
metastases, although neoadjuvant chemotherapy conferred no benefit, adjuvant 
chemotherapy was found to be associated with a survival advantage. In summary, the 
evidence base in this scenario is largely lacking, and to some extent conflicting. It 
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would appear that the scenario of “synchronous asymptomatic primary and resectable 
liver metastases” is not a homogeneous scenario to be treated by a “one size fits all” 
approach, but a very heterogeneous one, requiring approach flexibility by experienced 
MDT. Current evidence certainly does not justify neoadjuvant chemotherapy in all 
cases of synchronous resectable liver metastases; and (4) Symptomatic primary and 
resectable liver metastases. In this scenario, priority is given to dealing with symptoms 
from the primary as outlined in the section on symptomatic primary and 
unequivocally unresectable liver metastases. Thereafter however, once recovered from 
primary surgery, the next most appropriate treatment depends on the results of 
restaging. If restaging shows progression with now unresectable liver metastases, 
clearly chemotherapy is indicated. If restaging suggests disease progression in the 
liver though still resectable, then a period of systemic chemotherapy may be most 
appropriate to re-establish disease stability prior to reassessing with a view to liver 
resection. If restaging suggests stable and resectable metastases, then the scenario 
becomes similar in principle to the situation of “resectable primary and resectable liver 
metastases”, where the evidence for neoadjuvant chemotherapy prior to liver resection 
is not absolute, and there may be circumstances for proceeding to liver resection, with 
a view to adjuvant chemotherapy after.
Orthotopic liver transplantation for colorectal liver metastases
Some CRLM remain unresectable on account of proximity to vital structures that 
cannot be sacrificed, or because of insufficient remnant liver volume. However, the 
favourable results of liver resection in comparison to chemotherapy alone raises the 
question of whether total hepatectomy, followed by liver transplantation, might have a 
place in the management of unresectable liver only metastases.
Studies investigating OLT for unresectable CRLM during the 1990s reported poor 
outcomes in Europe and the United States with 5 year survival of 12%-21%[323,324], and 
thus much lower than outcome achieved following transplantation for other 
indications.
In 2006, on a background of improvements in both liver transplantation and CRLM 
management, and the favourable organ to recipient ratio in Norway, the Oslo 
University Hospital group initiated a study to reassess the survival of patients with 
non resectable CRLM after LT (SECA Trial)[325].
21 patients underwent deceased-donor LT, with 1, 3, and 5-year OS of 95%, 68%, 
and 60% respectively, thus comparing favourably to 19% OS in a comparative 
retrospective cohort of patients with unresectable CRLM treated with chemotherapy 
alone[326]. Median time to recurrence was 6 mo and all patients followed for longer than 
11 mo experienced recurrence, most frequently in the lungs[327]. Similarly, Toso et al[328] 
reported the outcomes of 12 patients who underwent OLT for unresectable liver 
metastases, with a 5 year OS of 50%, and with 4 out of 12 patients showing no sign of 
recurrence at 48 mo.
The wide inclusion criteria of the SECA 1 study allowed the identification of 4 
clinical features associated with a worse survival: Pretransplant tumor diameter > 5.5 
cm, a pre-transplant CEA > 80 μg/L, time interval from resection of the primary to 
transplantation < 2 years, and progression of the metastases under neo-adjuvant 
chemotherapy. These and other criteria have been used to inform more selective 
recruitment criteria to the ongoing SECA II trial, with preliminary results showing 
overall survival at 1, 3, and 5 years of 100%, 83%, and 83%, respectively[329].
Further trial are also in progress, including the TRANSMET (NCT02597348) and 
SECA III (NCT03494946) trials which compare OLT to optimal systemic chemotherapy 
in unresectable CRLM.
In conclusion, it appears that in selected patients with unresectable CRLM, OLT is 
associated with OS Figures which are comparable to those achieved for other OLT 
indications. The outcome of randomised trials comparing OLT to optimal systemic 
chemotherapy are eagerly awaited but results favouring OLT would doubtless 
contribute to the already complex debate regarding organ allocation.
SECTION 5: HISTOPATHOLOGICAL ASSESSMENT OF COLORECTAL 
LIVER METASTASES
Following resection of CRLM, histopathological assessment is essential, and yields 
critically important information which directly influences further management. The 
assessment of margins is an obvious example, affecting decisions regarding re-
operation, as well as the timing and intensity of surveillance. Another is the real 
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response to chemotherapy, which may influence oncological management. The 
following section describes current practice in CRLM histopathological assessment.
Current best practice
The role of histopathology is predominantly one of post-operative assessment of 
resected liver specimens, with pre-operative biopsy or intra-operative frozen section 
being required only rarely (the latter usually in the context of lymph nodes suspicious 
for metastasis, or unexpected subcapsular lesions not identified on preoperative 
imaging)[330].
Pre-operative assessment: Preoperative percutaneous needle biopsy is avoided where 
possible due to the risk of tumour seeding along the biopsy needle tract[330,331]. In rare 
cases were percutaneous liver biopsy is deemed to be necessary, usually in the context 
of multiple known primary tumours, the test can be modified to mitigate the risk of 
tumour seeding. Endoscopic ultrasound fine needle aspiration may be technically 
feasible in some cases, in particular for intra-abdominal lymph node sampling where 
reasonable yields can usually be obtained to allow for additional immunohisto-
chemical assessment, if required.
Routine haematoxylin and eosin (H and E) stained slides are examined in the first 
instance. A limited panel of immunohistochemical stains such as CK20 and CDX-2 can 
be used to confirm morphological findings suggestive of colorectal origin[332]. An 
expanded panel to include CK7 and other specific localising antibodies can be 
undertaken depending on morphological appearance and clinical history[330,332].
The biopsy report should contain a morphological description of the tumour 
including the degree of differentiation, details of immunohistochemical analysis, and a 
conclusion indicating the site, or possible sites, of primary origin. A description of the 
adjacent/background liver tissue should also be included as the presence of chronic 
liver disease may influence risk assessment for surgery and chemotherapy[333].
Post-operative assessment: The approach to the resected liver specimen involves both 
macroscopic and microscopic assessment. (1) Macroscopic assessment: The 
macroscopic assessment should include the size and weight of the resection specimen, 
along with a description of the capsule, including areas of disruption or adhesions. 
Surfaces other than the capsule are painted with ink to allow margin identification. 
Specimens can be sectioned fresh or fixed, with fixed tissues allowing for more 
accurate slicing[330]. An example of a fixed specimen is shown in Figure 4. Findings 
should be carefully correlated with the description in the operation note, especially in 
the case of complex specimens. Tumour deposit number and size should be assessed. 
It is also important to correlate with imaging data to ensure that all preoperatively and 
intraoperatively identified lesions are sampled for microscopic assessment. At least 
one block should be taken of each metastatic deposit, as well as one block of 
representative background liver[330]; (2) Microscopic assessment: The microscopic 
assessment should include a morphological description of any lesions present, 
including degree of differentiation. An example of the histological appearance of a 
colorectal metastasis is shown in Figure 5. Immunohistochemistry is not routinely 
carried out, but should be included if the morphological features are unusual or there 
is diagnostic uncertainty[330]. Other factors that are assessed include evidence of 
capsular breach by the tumour, distance to the resection margin (a distance of 1 mm or 
more being considered “not involved”), the presence or absence of lymphovascular 
invasion, and the number of involved lymph nodes, if present. The presence or 
absence of background chronic liver disease should be commented upon[330]. Molecular 
tests (KRAS, BRAF, NRAS, microsatellite instability) should also be conducted if not 
previously completed on the primary tumour[333]. The results of these molecular tests 
can be crucial for the selection of the most appropriate chemotherapy agent, to aid 
with prognostication, and to establish or exclude a diagnosis of a hereditary tumour 
syndrome[333]. The effect of preoperative neoadjuvant therapy should be evaluated if 
applicable. This includes an assessment of tumour response and the presence of 
chemotherapy-induced injury such as sinusoidal obstruction syndrome (more 
common with oxaliplatin) or steatohepatitis (more common with irinotecan) in the 
background liver tissue. The former can be assessed using the chemotherapy-induced 
sinusoidal injury score[333-347]. In cases where selective internal radiotherapy has been 
administered, therapeutic microspheres may also be present. If preoperative portal 
vein embolization has been undertaken then embolic material may be present within 
portal vein branches, along with variable degrees of parenchymal atrophy due to 
relative ischaemia, shown in Figure 6. Tumour response to chemotherapy involves 
assessing the percentage area of viable tumour compared to fibrosis and necrosis. The 
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Figure 4  Multiple colorectal metastases in a formalin-fixed liver resection specimen showing a pale cut surface with typical lobulated 
border. Non-capsular surfaces inked for margin identification (scale bar: 5 cm).
Figure 5  Colorectal metastasis with typical cribriform glandular architecture and central comedonecrosis (Hematoxylin-eosin staining, × 
10 magnification).
four tiered system advocated by the American Joint Committee on Cancer based on a 
modification by Ryan et al[335] is currently recommended by the Royal College of 
Pathologists for assessment of response in primary colorectal carcinoma (Table 1)[336] . 
While necrosis, as illustrated in Figure 7, is very common, there is evidence to suggest 
that the most predictive factor for outcome in the assessment of tumour response to 
chemotherapy is fibrosis (Figure 8)[333,337].
Future perspectives
Several biomarkers are under development which have both prognostic and predictive 
potential. One such marker is programmed cell death protein (PD-1), whose dominant 
ligand is PD-L1, expressed on the surface of activated T cells to regulate proliferation 
and activation. When carcinoma develops tumour cells may express PD-L1 and thus 
reduce their immunogenicity. Assessment of PD-L1 expression in tumour cells using 
immunohistochemistry may therefore provide prognostic information and predict 
response to treatment with PD-1/PD-L1 inhibitors. This has shown encouraging initial 
results reported in microsatellite instability-high colorectal carcinoma[337,339].
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Table 1 Assessment of response to chemotherapy in primary colorectal carcinoma using the Tumour Regression Score (AJCC)
Evaluation Tumour regression score
No viable cancer cells (complete response) 0
Single cells or rare small groups of cancer cells (near-complete response) 1
Residual cancer with evident tumour regression, but more than single cells or rare small groups of cancer cells (partial 
response)
2
Extensive residual cancer with no evident tumour regression (poor or no response) 3
Figure 6  Embolic material within a large portal vein branch, with adjacent adenocarcinoma, in a patient who underwent preoperative 
portal vein embolization (Hematoxylin-eosin staining, × 4 magnification).
Figure 7  Extensive confluent tumour necrosis with fibrosis in keeping with a partial response to neoadjuvant therapy (Hematoxylin-
eosin staining, × 4 magnification).
CONCLUSION
The management of colorectal liver metastases is highly complex owing to multiple 
treatment modalities. Adding to this complexity is the marked heterogeneity of the 
patient group, and the nuanced overlap between ‘different’ scenarios. In this context, 
no single specialty team, let alone individual clinician, is solely equipped to carry out 
optimal decision making.
Effective management results from careful and informed discussion from an 
experienced multi-disciplinary team involving radiology (cross sectional, nuclear 
medicine and interventional), Oncology, Liver surgery, Colorectal surgery, and 
Histopathology. Furthermore, it is incumbent on such MDTs to remain up to date in 
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Figure 8  Confluent fibrosis and dystrophic calcification without viable residual tumour cells, consistent with pathological complete 
response to neoadjuvant therapy (Hematoxylin-eosin staining, × 4 magnification).
what is a fast-evolving field. In the not distant future, geneticists and molecular 
biologists may be added to the list of specialty representatives required in MDT 
discussions.
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